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SUMMARY 
Background 
 An estimated 35% of tuberculosis (TB) cases worldwide are accounted by India and 
China alone. Pediatric TB accounts for 11% of TB cases worldwide. The most common type of 
TB in children is smear negative pulmonary TB. Data from the Revised National Tuberculosis 
Control Programme (RNTCP) in India indicate that in 2009, the percentage of new smear 
positive cases was 72% of the total case detection rate of 132/100,000. Of all the new cases 
detected, 7% were pediatric cases. Forty per cent of the population in India is thought to be 
infected with M. tuberculosis and the population has an estimated annual risk of infection of 
1.5%.  
 Due to difficulty in obtaining a sputum sample in children, M. tuberculosis very often 
goes undetected in smear and culture. In children <5 years, the tuberculin skin test (TST) is 
widely used as an aid in the diagnosis of TB infection. A decade ago, the QuantiFERON test 
(QFT), an Interferon Gamma Release Assay (IGRA) was approved by the Food and Drug 
administration (FDA) and European Medicines Agency (EMEA) and is now used as an aid in 
the diagnosis of TB infection. Although the TST is known for its limitations related to 
variations in dose, inter-observer errors related to administration and reading, potential lack of 
specificity related to non tuberculous mycobacteria (NTM) and Bacillus Calmette-Guerin 
(BCG) vaccination, it may have a higher sensitivity than the QFT. However, the available 
literature shows that QFT has a higher specificity and potentially higher predictive value than 
the TST.  
 Diagnosis of childhood TB remains a challenge. Although, QFT has shown promising 
results in few studies, there is limited data on its diagnostic performance in children. One of the 
limitations of the QFT in TB-endemic areas is that it will not differentiate between latent and 
active TB. However, in children – especially young children – all TB infection can be 
considered to be of recent origin and given the shorter duration of progression from infection to 
disease in these children, they are therefore at ‘high risk’ of developing TB. The available 
studies suggest that QFT may therefore prove clinically useful in the evaluation of TB in 
children and feasible to perform. There is a need to perform more studies in children in India to 
evaluate different tests in relation to TB infection and disease with a larger sample size in order 
to overcome the diagnostic challenge that exists in the field of childhood TB. The overall aim 
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of this study is to contribute to the diagnosis of TB infection and disease in young children in 
India, a high TB burden country. 
 
Methodology  
 The present study is nested within a prospective cohort study. BCG vaccinated infants 
<14 days of age and born to mothers from Palamaner taluk in Andhra Pradesh were enrolled. 
Informed consent was obtained and information such as age, weight of the infant, parents’ 
demographic characteristics, and socio economic data were collected from clinical records and 
by interview. Infants were randomly assigned to an active or passive follow up group and 
followed for 2 years. Infants suspected of having TB based on symptoms, failure to thrive 
(FTT) and a recent history of contact with TB were referred to the case verification ward 
(CVW) for diagnostic evaluation of TB. A TST and chest X-Ray was performed. One sample 
each of a gastric aspirate and induced sputum were collected on two consecutive days which 
were used for smear microscopy and culture. Mycobacterial cases were confirmed by 
speciation using Genotype MTBC and CM kit (HAIN) or COBAS TaqMan MTB test kit 
(Roche). Blood was collected, plasma isolated and QuantiFERON gold In tube assay (QFT-
GIT) performed.  
 
Results 
   There were 4,382 children enrolled in the study of which 2,215 were included in the 
active surveillance group and 2,167 in the passive surveillance group. Seven hundred and forty 
six participants were referred to the CVW of which 53 came for a second visit, three for a third 
visit and one for a fourth visit during the two year period of follow up. In 709 participants both 
TST and QFT-GIT were performed. The percentage of children who were TST positive was 
10.2% (n=72/709) while 5.8% were QFT-GIT positive (n=41/709).There were a total of four 
cases with definite (bacteriologically confirmed) TB; three of which were positive for TST and 
QFT. The 4th case was negative on culture, TST and QFT-GIT but was positive on smear 
microscopy. A direct polymerase chain reaction (PCR) on the induced sputum sample was 
positive for M. tuberculosis. There were 9 cases with ‘probable’ TB, of which one was positive 
for TST but negative for QFT-GIT and the rest were negative for both.  Children with a recent 
history of contact with a TB case had increased odds of being TST positive (OR 2.11[95% CI 
1.07; 4.17], p=0.03), QFT-GIT positive (OR 3.46 [95% CI 1.50; 7.81], p=<0.01) and combined 
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TST and QFT-GIT positive (OR 7.08[95% CI 2.51; 19.65], p=<0.01) in a univariate analysis.  
In a multivariate analysis, the association between TST positivity and recent history of contact 
with TB was not statistically significant (OR 1.58 [95% CI 0.69; 3.63], p=0.27). However, for 
QFT-GIT positivity the association with contact remained statistically significant in a 
multivariate analysis (OR 4.36 [95% CI 1.79; 10.54], p=0.01). Children with wasting based on 
the weight for height Z score (<-2SD) had reduced odds of being TST positive in a univariate 
analysis (OR 0.31 [95% CI 0.17; 0.56], p=<0.01) as also those with FTT (OR 0.19 [95% CI 
0.12; 0.33], p= <0.01]. There was no association between QFT-GIT positivity and nutritional 
status. The agreement between TST (cut off ≥10mm) and QFT-GIT was fair [κ 0.31 (95% CI 
0.19; 0.40), p=<0.01] and TST (cut off ≥5mm) and QFT-GIT was poor [κ 0.09 (95% CI 0.04; 
0.11), p=<0.01] for all children with both TST and QFT-GIT tests performed and referred to 
the CVW for the first time (n=709). The percentage of indeterminate QFT-GIT results was 
3.6%. 
 
Conclusion 
 The incidence of TST positivity was higher than that of QFT-GIT positivity. Due to a 
lack of a gold standard for the diagnosis of TB infection in children and the low number of 
bacteriologically confirmed cases, sensitivity and specificity of the tests in relation to TB 
infection and disease could not be calculated. A recent history of contact with TB was 
associated with QFT-GIT positivity, but not TST positivity in a multivariate analysis and this 
association was stronger when both TST and QFT-GIT positivity was considered together. 
Additional studies to confirm the utility of a two-step approach i.e. QFT-GIT test on those who 
are TST positive would be relevant. This approach would be strengthened if the likelihood of 
progression to TB disease was higher for those infants with combined TST / QFT-GIT 
positives rather than either test alone. TST and not QFT-GIT positivity was reduced in 
undernourished participants; this is significant given the high prevalence of under nutrition in 
children of this age group in India. The data suggest that QFT-GIT may be better for the 
diagnosis of a recent infection as compared to the TST in a setting where under nutrition is 
high. The overall agreement between TST and QFT-GIT was fair at a cut off of ≥10mm for 
TST. The number of indeterminate test results in the QFT-GIT was low.  
 
 
 4  
1.0. INTRODUCTION 
1.1. History 
Tuberculosis (TB) has a long history. Molecular analysis of skeletons from Egyptians 
have proved the presence of skeletal TB almost 5000 years ago (1). TB was also known as 
pthisis (meaning wasting away, consumption) a name which appeared in the Greek literature 
during the 5
th
 century AD (2). The TB epidemic started in Europe around the 17
th
 Century and 
continued for the next 200 years. It later came to be known as “The Great White Plague” (3) 
The natives of North America experienced a major outbreak of TB in 1880 and by 1886 
the death rates had increased to 9000 per 100,000 people. TB was rare among the natives of 
Africa living in small remote villages. However they experienced a high mortality rate when 
they were exposed to the disease when they came in contact with the Europeans. African slaves 
were free from the disease on their arrival in America. However, they developed TB and on 
return to their homeland, the TB mortality rose to 700 per 100,000 (3).  
TB was also documented in Asia i.e. India and China as early as 3300 and 2,300 years 
ago respectively, (2) but only towards the end of the 19
th
 century was a high incidence of the 
disease found in these two countries (3). 
 
1.2. The organism and its transmission 
 On 24 March 1882, Robert Koch - a German physician - demonstrated the bacillus 
which causes TB at the Berlin Physiology Society meeting (4). This bacillus was later called 
Mycobacterium tuberculosis.  
 TB is transmitted through air (5). TB infection occurs due to the inhalation of infective 
droplets, which are usually less than 5µm in diameter (6). The risk of infection depends on the 
duration, probability, proximity to exposure, intensity of an exposure and also on the 
infectiousness of the source (7, 8). 
 TB is known to be contagious and if untreated, each infected individual with active TB 
is capable of infecting 10-15 people on an average every year (5). 
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1.3. Pathogenesis and Immunology 
 Infectious individuals transmit the organisms through air via droplet nuclei (9). The 
larger droplet nuclei which are around 10µm in diameter are carried by air and when inhaled 
by a healthy individual typically land in the upper respiratory tract but do not progress further 
due to the action of the mucus and ciliary system of the respiratory tract. The smaller droplet 
nuclei which are 5µm or lesser in diameter can escape the actions of the mucus and ciliary 
system of the respiratory tract and manage to penetrate further and land in the bronchioles and 
the alveoli. The alveolar macrophages then phagocytose the inhaled bacilli. They are, however, 
unable to kill the bacteria and these bacteria continue replicating within the macrophages. 
These infected macrophages are then transported to the lymph nodes from where the 
mycobacteria move to other lymph nodes and organs like the kidney, spinal cord and other 
organs leading to extra pulmonary tuberculosis (3, 10). 
A cell mediated immune response develops after 2-3 weeks of initial infection. The T 
helper (Th) cells activate the macrophages which aid in ingesting and digesting the intracellular 
bacteria while the T cytotoxic (Tc) cells lyze the macrophages resulting in the formation of 
caseous granulomas with central necrosis (3). 
 The primary infection site, characterized by a single lesion and involvement of the 
draining lymph node is called the Ghon complex (3) and the appearance of this in chest 
radiographs is considered a classic sign of M. tuberculosis infection. 
 
1.4. Risk of progression from TB infection to disease in infants and children 
 Since infants have a less developed immune system as compared to adults and school-
children, they have a higher probability of developing a disease following infection. The 
progression of infection to disease varies with age as shown in Table (a), below. Infants are at a 
higher risk of progressing to pulmonary TB disease as compared to children between 2-5 yrs of 
age. Since more than 90% of children progress to disease within 12 months of primary 
infection, all children below 3 yrs of age and/or immune compromised children can be 
categorized as a high risk group (11). 
 In most of the cases, infection is caused by exposure to an infectious pulmonary TB 
individual within the household (12). Most infections progress to disease within a year 
following infection. However, some may progress within 2 years. In a healthy infant with no 
signs or symptoms of TB but suspected to have TB infection, the only evidence is often a 
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positive tuberculin skin test (TST). In the majority of cases the source of exposure in an infant 
is the mother (6). 
Table (a). Average age specific risk for disease development following primary infection  
 
Age at primary 
infection (yr) 
Pulmonary disease 
(%) 
 
Miliary or central 
nervous system TB 
(%) 
 
 
< 1 
1-2 
2-5 
5-10 
>10 
 
 
30-40 
10-20 
5 
2 
10-20 
 
 
10-20 
2-5 
0.5 
<0.5 
<0.5 
 
Adapted from Marais et al. The natural history of disease of childhood intra-thoracic tuberculosis: a critical 
review of the prechemotherapy literature. Int J Tuberc Lung Dis 2004;8(4):392–402 (11) 
 
 A child infected with TB is vulnerable and can develop the disease at any given point 
of time. A weak immune system (as in the case of HIV) is the major factor contributing to the 
progression of infection to disease. However other infections (such as whooping cough and 
measles) and malnutrition which is common in infants and early childhood in developing 
countries may also contribute to it (6). 
 
1.5. Epidemiology of childhood TB  
 TB is also referred as a “disease of poverty” and the majority of deaths due to TB occur 
in developing countries, with more than 50% of deaths occurring in Asia. There were 9.4 
million new TB cases worldwide in 2009 of which, an estimated 1.0-2.0 million cases were 
seen in people with HIV (13). Tuberculosis in children is often neglected since children are 
often considered ineffective transmitters of the bacillus (14). However the World Health 
Organization (WHO) reported that “childhood tuberculosis accounts for 11% of the TB cases 
worldwide and about 1 million children develop TB annually worldwide”(15). 
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1.5.1. World Scenario 
 The WHO reports that “most of the estimated cases of TB occurred in Asia (55%) and 
Africa (30%), with small proportions of cases in the Eastern Mediterranean Region (7%), the 
European Region (5%) and the Region of America (3%)”. An estimated 35% of TB cases 
worldwide are accounted for by India and China alone (13).  
 In a study in a high prevalence region in South Africa, of 1,445 neonates who were 
followed for 2 years, 69.5% had a contact with an infectious source and 11.9% were culture 
positive for M. tuberculosis (12).  
In 2007, in the United States (US) 13,000 new cases of TB disease were diagnosed, out 
of which 820 were children younger than 15 yrs of age. TB rates were 9.5 times higher in the 
foreign born individuals in the US as compared to those of US origin. Most of the cases 
occured in people coming from Mexico, Philippines, Vietnam, China and India (14). 
In Japan, from the 1970’s, there was a drop in the number of newly notified childhood 
TB cases between 0-14 years of age. However the age group between 0-4 years has 
consistently shown the highest occurrence since the 1970’s. In 2008 the incidence rate of 
pediatric TB was 0.55 per 100,000 population (16). 
 
1.5.2. Indian scenario 
 In India, 40% of the population is thought to be infected with TB and the annual 
risk of infection is 1.5% (17). In 2009, 1/5
th
 (21%) of all the TB cases in the world were found 
in India alone (13). 
 In 2009, the total population covered by the Revised National Tuberculosis Control 
Programme (RNTCP) was 1,16,41,00,000. The total annualized case detection rate was 132 per 
100,000 population, 624,617 new smear positive cases, 384,113 new smear negative cases and 
233,026 new extrapulmonary cases were registered under the RNTCP. The annualized new 
smear positive case detection rate was 54 per 100,000 population. Out of all new cases 
detected, 86,532 (7%) were pediatric cases. Cure rate of the new smear positive cases were 
85% (18). 
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1.6. Diagnosis of TB in children   
 Diagnosis of TB in children remains a challenge. In children, contact with an adult with 
TB is important (12). Due to difficulty in obtaining sufficient sputum sample in children, the 
sputum smear microscopy (standard means for diagnosis of TB) and culture (considered gold 
standard for diagnosis of TB) fail to be used to diagnose TB in children. However the 
bacteriological yield is higher in children with advanced disease. In low endemic countries, a 
history of contact with an infectious source accompanied with a positive skin test and abnormal 
suggestive chest radiograph is used to diagnose TB and has worked well in such settings (19).
 In some settings structured diagnostic algorithms are used. In a study in South Africa, 
structured diagnostic algorithms were compared for their ability in diagnosing childhood 
tuberculosis and the approaches categorized as binary (positive or negative), hierarchical 
(definite, probable, possible, unlikely or not TB) and numerical (score >x = TB). The study 
showed that compared to the binary outcomes, the related hierarchical approach showed better 
agreement (12). 
 
1.7. The tuberculin skin test 
 The tuberculin skin test (TST) also known as the Mantoux test is widely used as an aid 
in the diagnosis of TB. Delayed type hypersensitivity (DTH) reactions are involved in the TST. 
The DTH is a localized inflammatory reaction which is induced by the cytokines secreted by 
activated Th cells on encounter with certain types of antigens. The DTH was first observed by 
Robert Koch in 1890 when individuals infected with Mycobacterium tuberculosis, who were 
injected intradermally with a filtrate derived from mycobacterial culture, developed a localized 
inflammatory response. This kind of localized skin reaction was called as a “tuberculin 
reaction”. Tuberculin is a purified protein derived (PPD) from heat-killed tubercle bacilli (20). 
Usually, the tuberculin, PPD-RT23, in a 0.1 mL dose, equivalent to 2 TU (tuberculin units), or 
PPD-S, equivalent to 5 TU, is injected intradermally by trained personnel and is read after 24-
48 hrs. A positive reaction is indicated by an induration of ≥10mm, although lower cutoffs may 
be used in immunocompromised states such as HIV. A positive TST is not diagnostic test for 
TB disease by itself but only indicates TB infection. A negative test does not always exclude 
the possibility of having TB (3). 
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1.7.1. Weaknesses and Strengths 
 Even though the TST has been used for the diagnosis of TB for more than a 
century, tuberculin, which is a crude mixture of many antigens, is known to cross-react with 
NTM and the BCG vaccine and give false positive results (21). A positive result may also 
result from a past infection with Mycobacterium tuberculosis. It is also known for its 
limitations in accuracy and reliability (22). Moreover, TST reading needs to take place 48-72 
hours after the administration of the tuberculin which requires the patient to visit the 
hospital/place of administration twice. Variability in doses, manufacturers, errors in 
administration and reading cut off values leads to variable results. In immune-suppressed 
patients and in malnourished children false negative TST results may occur (23). 
 One of the major advantages of the TST is low cost - it is less expensive than the new 
Interferon-γ Release Assays (IGRAs) and in some studies in children, has been shown to have 
a higher sensitivity than the IGRAs (24, 25). It is also readily available.  
 
1.7.2. TST and TB infection/TB Disease 
 The TST is routinely used as an aid for the diagnosis of TB infection. In children <5yrs 
TST is generally used for identifying TB infection (26). TB disease is distinguished from TB 
infection in that TB disease usually has associated signs and symptoms and abnormal chest X-
rays after the infection.  In adults, it is easier to differentiate between infection and disease 
since the disease often occurs as a result of reactivation of dormant bacilli acquired during a 
previous infection, giving time for a robust immune response to develop. However, in children 
it is not so well defined as more often initial or primary infection progresses rapidly to disease 
(6).  
 
1.7.2.1. TST and TB infection 
  In a contact investigation, individuals with lower levels of recent exposure were more 
likely to be positive by TST, suggesting that TST may be better at detecting a remote infection 
which was present before the recent exposure (27) – though an alternate explanation may 
simply be that these results were false positives. 
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In children, as in adults, latent TB infection lacks a diagnostic gold standard.(14) Many 
studies have compared the TST to different IGRAs and indicated that the TST has lower 
specificity than the IGRA (24, 28, 29). 
 
1.7.2.2. TST and TB disease 
 In a study involving 28 children aged 4 months to 7 yrs with culture confirmed active 
TB, TST showed a sensitivity of 100% (24). In another study with 25 children with culture-
confirmed active TB, sensitivity for TST was estimated to be 88% at a cut off of ≥10mm and 
83% at a cut off of ≥15mm. When children with probable active tuberculosis were included 
(defined on the basis of epidemiologic, clinical, and radiographic findings in the absence of a 
positive culture), the sensitivity of TST fell to 71% at a cut off of ≥10mm and 60% at a cut off 
of ≥15mm (25). In a study in Taiwan the clinical symptoms and demographic characteristics of 
103 children were studied and children with probable and confirmed TB were enrolled and 
TST performed. TST was positive in 69.6 % of the cases with pulmonary TB (probable and 
confirmed TB) (30). 
 Due to the low cost, lack of requirement of laboratory equipments like pipettes, enzyme 
linked immunosorbent (ELISA) reader, computer to analyze the data, extensive training issues 
and ready availability as compared to the IGRA (31), TST continues to remain the test of 
choice in many countries (17).  
 
1.7.3. Indian Scenario 
 In a 15 year follow-up study in Southern India, a randomized control trial which 
involved 280,000 individuals, showed that TST positivity was significantly associated with the 
development of TB (32). In a study conducted in Southern India, Gopi et al showed that BCG 
vaccination did not interfere with the tuberculin survey to estimate the annual risk and rate of 
tuberculosis infection [ARTI] (33). Some studies have shown that BCG induced tuberculin 
response after vaccination ranges from 1-19mm induration (34, 35). Many factors influence the 
size of the induration produced in response to the tuberculin after BCG vaccination such as 
manufacturer of BCG, dose and method of manufacture.  
As mentioned earlier, many studies conducted in India (17, 36-38) suggest, that in spite 
of its limitations in accuracy and specificity, TST may be a useful tool for the diagnosis of TB 
mainly because of its low cost and ready availability and due to the fact that BCG vaccine in 
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infancy has limited effect on TST results in later life, including in older children and adults 
(33). 
 
1.8. The QuantiFERON test 
 Until 2001, the TST was the only immunological test which was available for 
the diagnosis of TB infection (39). Many studies (40, 41) led to the recognition of the role of 
Interferon-γ (IFN- γ) in the regulation of the cell mediated immune response to TB infection 
which paved the way for the application of the IGRA in the diagnosis of TB infection. The 
QuantiFERON TB test (QFT) (Cellestis Limited Victoria, Australia) was the first IGRA test 
which was approved by the Food and Drug Administration (FDA) to be used for the diagnosis 
of TB infection in 2001 (42). The guidelines for the use of this test was published by the Center 
for Disease control (CDC) in 2003 (43).This test used an ELISA to measure the IFN-γ released 
in response to the PPD when compared with the controls. Inspite of using a control for 
nontuberculous mycobacterial sensitization (M.avium antigen) and saline as a negative control, 
the test showed lower specificity when compared to the TST (44). Genomic analysis of M. 
tuberculosis helped determine the M. tuberculosis-specific antigens; early antigenic secretory 
taget-6 (ESAT-6) and culture filtrate protein -10 (CFP-10). These antigens are known to induce 
the production of IFN-γ in sensitized Th cells. These two antigens were absent from the BCG 
strain and from most NTM and hence test results were not confounded by BCG vaccination 
and infection with NTM (45). The QuantiFERON TB Gold test (QFT-G) (Cellestis Limited, 
Victoria, Australia) was the second IGRA test approved by the FDA for the diagnosis of TB 
infection in the year 2005 (46). The guidelines were published by the CDC in the same year 
(47). In this test the whole blood was incubated separately with the two antigens (ESAT-6 and 
CFP-10) and the plasma collected. The amount of IFN-γ released was calculated as the 
difference in IFN-γ concentration in the plasma from the blood sensitized to the antigens minus 
IFN-γ concentration in plasma from blood incubated without an antigen (47).  
The ESAT-6 and CFP-10 antigens are present in M. kansasii, M. szulgai and M. 
marinum which may lead to cross reaction which in turn may lead to false positivity, though 
studies have shown that human infections with such pathogens seem to induce low levels of 
IFN-γ (48). As these antigens are recognized by fewer T lymphocytes and often stimulate less 
IFN-γ compared to PPD, a more sensitive ELISA than the one used in QFT was needed (43). 
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 In 2007, QuantiFERON-Gold In-tube assay [QFT-GIT] became the third IGRA test to 
be approved by the FDA (49). This test used ESAT-6, CFP10 and an additional antigen, TB 
7.7 and the blood was collected in tubes coated with a mixture of the 3 antigens and one 
negative control and one containing heparin, dextrose and phytohemogluttinin which served as 
a positive control. 
  The TB response was calculated as difference in IFN-γ concentration in plasma from 
blood stimulated with a mixture of the antigens minus the IFN-γ concentration in plasma from 
blood incubated without antigen (i.e., nil). This test was evaluated in the US and a number of 
other countries and the interpretation criteria promulgated. Tests with a nil of 0.7–8.0 and a TB 
response of 25%–50% of nil were interpreted as positive rather than as indeterminate. Also, 
tests with a nil of 0.7–8.0 and a TB response that is <25% of nil were interpreted as negative, 
whereas for QFT-G they were interpreted as indeterminate (26, 47). 
 The T-SPOT.TB became the fourth IGRA to be approved by FDA in 2008. In this test, 
peripheral blood mononuclear cells (PBMCs) are incubated with control materials and two 
mixtures of peptides from ESAT-6 and CFP-10. An enzyme-linked immunospot assay 
(ELISPOT) is used to detect increase in the number of cells that secrete IFN-γ (represented as 
spots in each test well) after stimulation with antigen as compared to the media control (nil) 
(50). The TST, QFT-GIT and T-SPOT.TB showed sensitivities of 95%, 91% and 84% 
respectively when pooled sensitivity was calculated from three studies (24, 25, 51). The largest 
study was carried out with culture confirmed active TB in which the estimated sensitivity of 
TST, QFT-GIT and T-SPOT.TB were 94%, 83% and 95% respectively (51).  
 
1.8.1. Strengths and Weaknesses 
 In general the specificity of QFT is considered to be higher than the TST as the proteins 
included in the QFT are encoded within the region of difference 1 (RD1) of the M. tuberculosis 
genome and hence are more specific to M. tuberculosis than the PPD. These proteins are not 
shared with the BCG strains and many of the NTM (28). QFT is a quantitative laboratory assay 
and hence is not subject to the kind of bias and inter-observer errors which are seen in TST 
which occur during TST injection and reading of the induration (26). 
 In addition to the kit which is not readily available in most high TB endemic countries, 
the QFT requires skilled, trained technicians, and lab equipment such as incubator, calibrated 
pipettes, a micro plate reader and shaker. It is also prone to cross contamination (31). There are 
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limited published data evaluating IGRA performance in children. Compared to adults the 
IGRA performance in children is less well understood since there are very few studies which 
provide separate results for children and adults and even fewer, segregate results by narrow 
age-categories. Second, the frequency of indeterminate IGRA results in children vary greatly 
from 0-17% and also vary greatly between different IGRA tests (52-56). Although low IFN-γ 
is produced in response to mitogen for majority of the indeterminate results, the reason for this 
low response in children is unclear. It is thought that lack of immunological maturity in young 
children may lead to the lower IFN-γ produced in response to mitogen. The indeterminate 
results can also be affected by the differences in the concentration of TB antigen and mitogen 
used for stimulation and differences in interpretation criteria especially, in case of different 
IGRA tests. There is also a concern regarding the low sensitivity of the IGRAs when compared 
to the TST (24, 57). 
. 
1.8.2. QFT and TB infection/TB disease 
1.8.2.1. QFT and TB infection 
 In four studies which involved individuals unlikely to have TB infection, the pooled 
specificity was calculated. For QFT-GIT pooled specificity was found to be 99% and for TST 
was found to be 85% (24, 58-60). The low specificity for the TST may be due to false positive 
TST results following BCG vaccination or exposure to NTM. 
 
1.8.2.2. QFT and TB disease 
 In a study in Germany which involved 601 individuals with culture confirmed active 
TB, the QFT-GIT was reported to perform better than the TST (at a cut-off of 5 mm) in 
predicting subsequent active tuberculosis in untreated contacts. Out of 219 contacts that had an 
induration of ≥5mm, five progressed to disease whereas out of 41 contacts that had positive 
QFT-GIT, six progressed to TB disease (61). 
         In a study in Australia, QFT was positive in 83% cases in individuals with proven active 
disease, 59% in those treated with TB previously and 80% in those exposed but who were TST 
negative (41). In two studies involving children with culture confirmed active TB QFT showed 
a sensitivity of 93% and 80% respectively (24, 25). Many studies have been performed using 
the QFT in a number of countries in the world and depict very promising results. All of these 
suggest that the QFT has a higher specificity than the TST (24, 25). 
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1.8.3. Indian scenario  
 There are very little data published on QFT studies performed among children in India. 
In a study in India, 105 children suspected of TB or had a history of contact with TB were 
admitted to the hospital for the diagnosis of TB (56). The agreement (κ=0.73) between QFT-
GIT and TST was good. BCG immunization was not associated with positivity of either of the 
tests. However, the agreement between the two tests are likely to be variable in different 
childhood populations (51, 52) with varying socio-demographic and nutritional characteristics. 
  
1.9. Comparison between TST and QFT 
  The TST and QFT are aids in diagnosing TB infection.  These tests can be used to 
identify individuals who are likely to benefit from a treatment which includes individuals who 
are or will be at increased risk to TB infection or may progress to active disease if infected 
(26). 
 In two reports of a TB contact investigation, greater recent exposure which was 
measured by infectiousness of the source and duration of exposure was more strongly 
associated with positive QFT results than the TST. This suggests that QFT may be better than a 
TST in detecting any recent infection. In the same studies, individuals with a lower amount of 
exposure were more likely to be TST positive than QFT positive which suggests that TST may 
be better than QFT in detecting remote infections (27, 62) – or that the TST generated more 
false positive results. However, in two studies neither of the tests showed any difference in the 
proportion of children with recent and remote exposure to active TB (63, 64). This may, in 
part, be due to a small sample size. 
 In a study including 28 children between 4 months to 7 years of age, the sensitivities for 
TST and QFT-GIT were 100% and 93% respectively. These children had active TB which was 
confirmed by culture (24). In a similar study among 25 children the sensitivity of TST at 
≥10mm was 88% while that for QFT-GIT was 80%. However, when children with probable 
TB (which was defined based on the clinical, epidemiologic and radiographic findings but 
absence of positive culture) were included, the sensitivity for TST at ≥10mm dropped to 71% 
(25). 
 15  
 In studies comparing the TST to QFT in children, the agreement between TST and QFT 
is variable and varies between 0.17-0.86.(24, 53-56, 65-71). However, the results cannot be 
compared across studies since the objectives of the studies were different and hence they 
followed different inclusion and exclusion criteria and were designed differently. The 
concentration of tuberculin used was different across the studies and was obtained from 
different manufacturers. This could lead to variations in the TST results. Some studies used 
QFT- G (66, 72) while others used QFT-GIT (24, 67) while one used both (73). It is also 
difficult to pool the sensitivities of the QFT and TST due to these variations. Moreover, the 
TST and QFT reading vary across different studies, being affected by the source of population, 
criteria for the interpretation of tests, prevalence of infection and proportion of infections 
confirmed by smear and culture, estimates of recent and remote exposure, recent TST 
performed, BCG vaccination and co-infection with other diseases like NTM disease and HIV. 
A recent meta-analysis by Machingaidze et al showed that for diagnosing active TB disease in 
children, the sensitivity of QFT was reduced in TB high-burden countries as compared to low-
burden countries (74). There is little published data from India comparing the TST and QFT in 
children, moreover, these studies are limited by their small sample sizes (56). Hence, in India 
we need studies which include a larger sample size of children of the younger age group 
especially children ≤ 3 yrs as this age group is at a higher risk of progressing to TB disease.  
 
1.10. The challenges faced 
The most common type of TB in children is smear negative pulmonary TB. The smear 
negativity is, in part, due to the fact that it is difficult to obtain sufficient sputum sample from 
children for smear microscopy. Moreover, cavitating TB is infrequent in children (6).  
 In India the available literature on IGRAs show that IGRAs have a better specificity 
than the TST which is carried out routinely in the population. The first study performed to 
evaluate the QFT tests in India was conducted in rural India by Dogra et al (56), but was 
limited by its small sample size.  
 Thus, pediatric TB which, until recently, remained a neglected portion in the field of 
TB continues to be a diagnostic challenge. There is a need to develop and evaluate newer 
diagnostic tools to improve the detection of cases of TB. IGRAs have shown promising results 
in some studies (29, 75-77) but, there are very few published data available on their diagnostic 
performance in children and infants. The studies which are available suggest that the IGRAs 
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may be feasible and in some cases may also prove clinically useful in the evaluation of TB in 
children. 
 
2.0. RATIONALE 
 Pediatric TB continues to remain a diagnostic challenge. Due to the paucibacillary 
nature of the infection and difficulty in obtaining a sputum sample in children, M. tuberculosis 
often goes undetected in smear and culture in children. Moreover, treatment is started on the 
suspicion of TB. Thus, in the absence of a gold standard, an alternative test is necessary to 
diagnose TB infection and TB disease and distinguish the two. The TST is generally used as an 
aid in diagnosing TB infection in children <5 years of age though it is known to have its 
limitations. Gopi et al (33) have shown that TST was not affected by BCG. QFT-GIT has also 
been used worldwide to diagnose TB infection. There is only one study from India (56) which 
compares the TST with QFT in children for the detection of TB infection. A greater number of 
studies are required to determine the diagnostic utility of the QFT-GIT for the diagnosis of TB 
infection and disease in children in India. Given the high prevalence of under nutrition in 
children <3 years of age in India and the fact that there are some data that TST is affected by 
under nutrition, an alternative test that performs reasonably well in immunocompromised states 
(including that associated with under nutrition) would be useful. The QFT-GIT has been shown 
to perform better than the TST in immunocompromised states, including HIV. This study 
explores the utility of the TST and QFT-GIT in a typical rural population in Southern India, 
with a relatively high burden of under nutrition. 
 
3.0. OBJECTIVES  
3.1. General Objectives 
 To contribute to the diagnosis of TB infection and disease in young children in India, a 
high TB burden country.  
 
3.2. Specific Objectives 
a) To compare and evaluate the TST and QFT-GIT for the diagnosis of TB infection and 
disease in young children in Southern India. 
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b) To determine the extent to which TST / QFT-GIT positivity is associated with 
demographic, clinical, nutritional and mycobacteriological (other than M.tuberculosis) 
characteristics. 
c) To determine the proportion of indeterminate test results in the QFT-GIT test. 
 
4.0. METHODOLOGY 
4.1. Study site  
Palmaner (Palamaner) taluk is situated in Chitoor district (Figure a), Andhra Pradesh in 
Southern India. It is located at 3.200
0
 N and 72.7500
0
E. It is elevated at 683 m above sea level.  
Figure a. Map of study area       
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The Palmaner taluk is further divided into smaller units called “mandals”. In our study 
we included 7 mandals from Palmaner taluk and the neighbouring Kuppam taluk.  The 7 
mandals comprised of 550 population units. These 550 population units covered a population 
of 400,000. 
 
4.2. Study design  
 The present analysis is nested within a prospective cohort study carried out in infants 
enrolled within 14 days of date of birth and followed up for 2 years in Palamaner taluk in 
Andhra Pradesh, Southern India.   
 
4.3. Study population 
 Infants less than 14 days of age and vaccinated with BCG within 72 hours of birth,  
born to mothers who were permanent residents of Palamaner taluk or in case of migration,  
who could provide contact information for the purpose of further follow ups were recruited  
and followed up for 2 years. These infants were further assigned to the active (bimonthly home 
visit to check for recent contact to TB, symptoms and anthropometry) or passive follow up 
surveillance group (TB education given but with no scheduled periodic home visits). 
 
4.4. Selection and screening of the participants 
 The pregnant women participating in the study were identified antenatally, most often 
in the second trimester by the study staff working in the community and followed up through 
their pregnancy. They were informed about the study during the post-natal period either while 
they were still admitted for delivery or at home after they had been discharged. Newborns were 
eligible for entry into the study if BCG vaccine was administered within 72 hours of birth and 
parental informed consent obtained within 14 days of birth. 
 Following informed consent the infants were assigned to active and passive 
surveillance groups and followed up for two years after birth.  
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 At the time of enrollment the mother of the child was provided a child health card, 
which helped the mother to track important health information such as vaccinations received. 
All mothers were asked to contact the study office if the infant or child was diagnosed with TB 
or if the child developed any symptoms suggestive of TB or a recent exposure to TB disease. 
Clinicians and others who would know of a death of an infant were asked to contact the study 
office in case of deaths of infants enrolled in the study. All participants were provided with a 
Study Identification Card and were asked to show it to their treating physician. The card had 
the subject study ID number and the study physician contact details.  
 Children with either symptoms suggestive of TB, failure to thrive (FTT) or contact with 
a TB case were referred to the case verification ward. Information on the infant’s birth weight, 
date of vaccination, name of the family doctor were obtained from the clinical records.  
 
4.5. Inclusion and exclusion criteria 
4.5.1. Inclusion criteria 
 All the participants had to meet the following criteria at the time of enrollment. 
1.  Vaccinated with BCG within 72 hours of birth 
2.  Enrolled within 2 weeks of date of birth 
 
4.5.2. Exclusion criteria  
 The subjects were not included in the study if they didn’t meet the following criteria at 
the time of enrollment. 
1) Parent/guardian declined to provide informed consent 
2) The entire family planned to move out of Palamaner taluk area within the next 2 
years 
 
4.6. Baseline evaluations 
 The following information was collected from clinical records and/or by interview 
a) Infant’s birth ( weight, gender) 
b) BCG vaccination 
c) Demographic characteristics  
d)   Socio-economic data (parental education, type of house and cooking fuel) 
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4.7. Diagnosis of TB and case verification 
 Infants who had symptoms suggestive of TB, FTT (based on any of the following 
criteria after evaluation of the weight for age growth chart; a)loss of weight or no gain in 
weight over two consecutive visits, b) Crossing of two centile lines, downwards on growth 
chart, c) weight consistently remaining below the third percentile line) and/or a recent contact 
with TB were admitted and further evaluated in a diagnostic ward (Figure b) at Emmaus Swiss 
Hospital which is referred to as the “Case verification ward” (CVW).   
 On admission, a TST was performed by a trained health care worker/nurse/doctor. This 
was read 48 hours later prior to discharge of the infant. 
 A blood sample was also taken at admission, out of which 3 ml was apportioned to 
QFT-GIT assay. Blood was drawn for other clinical tests as well. The blood drawn during a 
diagnostic visit did not exceed 8 ml. A heel prick was done and hemoglobin estimated prior to 
drawing the blood. The total volume of blood drawn or the decision not to draw blood was 
based on the treating physician’s assessment and the hemoglobin (Hb) report. Blood was not 
drawn if the Hb was below 10 grams/deciliter. A chest radiograph (AP view) was also obtained 
during the admission. 
 The next morning a gastric aspirate wash was collected and induced sputum obtained 
for smear and culture. The same procedures were repeated on the subsequent day.  
 The sputum samples were digested and decontaminated using the N-acetyl L-cysteine 
(NALC)-sodium hydroxide method. The induced sputum and gastric aspirate (collected in 50 
ml tubes) were diluted with 0.5% NALC dissolved in sodium hydroxide (4%)-sodium Citrate 
(2.3%) solution in a ratio of 1:1. The tubes were incubated for 15 min at room temperature with 
intermittent swirling. At the end of incubation Phosphate buffer saline (PBS [pH 6.8]) was 
added up to the 45 ml mark on the tube. The tubes were then centrifuged at 3050 relative 
centrifugal force (rcf) for 15 minutes at 4
0
C. After centrifugation, the supernatant was 
discarded and the sediment was resuspended using 1.5ml-2ml of the PBS. 300 µl of the 
sediment was inoculated onto Lowenstein Jensen (LJ) media and 500 µl into the Mycobacterial 
Growth Indicator Tube (MGIT) respectively. A smear was also simultaneously prepared on a 
glass slide for smear microscopy (Figure 2). These slides were heat fixed and stained with 
auromine O dye, destained using acid alcohol and counterstained with potassium permagnate. 
The slides were then observed under the fluorescent microscope.  
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 The LJ and MGIT were followed up for 8 weeks. Samples which showed growth on LJ 
or MGIT were classified as “positive for culture” after confirmation by Ziehl-Neelsen staining. 
For Zeihl-Neelsen, the heat fixed slides were stained with concentrated carbol-fuchsin filtered 
through a Whattmann No. 1 filter paper and allowed to stand for 5 minutes. The slides were 
gently heated using a spirit lamp intermittently. The slides were destained using 25% sulphuric 
acid for 3 minutes. The slides were then counterstained with methylene blue. After each step 
the slides were rinsed with distilled water. Once the slides were dry they were observed under 
the light microscope. A positive and negative control slide was included in every batch 
  
Figure b. Flow chart for the neonatal cohort study  
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All positive cultures were speciated using the HAIN MTBC kit (78) to exclude NTM 
and BCG disease. For  those who were culture negative but who had x-ray findings suggestive 
of TB, direct PCR on induced sputum or gastric aspirate samples were done using the Roche 
real time PCR kit (79). All subjects who were sputum positive were put on treatment.       
 A diagnostic algorithm was used to classify patients as ‘definite’ TB, ‘probable’ TB, 
‘possible’ TB, ‘unlikely’ TB and ‘Not’ TB (Figure c).  
 
 
Figure c. Diagnostic algorithm for TB classification of children referred for a diagnostic 
workup 
1. Mantoux ≥ 10 mm  
2. Cough > 2 weeks 
3. FTT or recent loss of weight (rLOW) 
4. Recent history of contact with a TB case 
  
 Culture positive OR ( smear and PCR positive) 
 
Yes                       No                 X-ray compatible/suggestive of TB?                                         No 
 
                                                Yes                                    
                                                                                                                               Diagnosed as TB by treating physician 
 
                                     1 or more additional features mentioned above 
                                                                                                                                                   Yes              No 
 
                                          Yes                      No                                             2 or more additional        2 or more additional 
                                                                                                               features mentioned above     features mentioned above 
                                                                                             
 
                                                                                                                   Yes                   No                Yes                No 
 
 
 DEFINITE TB      PROBABLE  TB                         POSSIBLE   TB                           UNLIKELY TB                  NOT  TB 
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4.8. Tuberculin skin testing 
 The TB suspects received a TST of 2 TU (Span Diagnostics Ltd, India) which was 
administered by a trained health care worker/nurse/doctor. The test was read after 2 days. An 
induration of ≥10mm was used as a positive cut off for TST. 
 
4.9. Sample collection 
4.9.1 Blood 
 Blood was collected on the day of admission. One ml of blood was collected in each of 
the TB antigen, nil antigen and mitogen tubes for QFT-GIT respectively.  
 
4.9.2 Gastric aspirate and induced sputum 
  The gastric aspirate and induced sputum samples were collected on 2 consecutive days, 
in the fasting state, early in the morning. For the gastric aspirate, an infant feeding tube was 
inserted into the stomach of the child and the contents were aspirated and collected in a 50 ml 
tube containing 10% sodium carbonate. This was followed by a stomach wash using normal 
saline (0.9% sodium chloride). For the induced sputum, nebulization was performed with 
hypertonic saline and the secretions following cough were collected using an infant mucous 
extractor into a 20 ml tube.  
 
4.10. Sample transport and receipt  
The gastric aspirate and induced sputum samples were transported using ice packs to 
maintain the temperature at approximately 4
0
C. The samples were received by the laboratory 
personnel. The details namely participant identification number (PID), age, gender and type of 
sample (gastric aspirate or induced sputum) were entered in a register and a Lab ID was 
assigned. 
 
4.11. QuantiFERON TB Gold In tube assay 
4.11.1. Principle 
  The QFT-GIT uses specialized blood collection tubes, which are used to collect whole 
blood. Blood is incubated for 16-24 hours, after which, plasma is harvested and tested for the 
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presence of IFN-γ produced in response to the peptides of the antigens ESAT-6, CFP-10 and 
TB 7.7.The assay was performed according to the instructions provided in the kit (31). 
 
4.11.2. Materials provided 
1) Nil control, TB antigen and mitogen Control tubes 
2) Microplate strips 
3) Lyophilized Human IFN-γ standard,  
4) Diluent, Lyophilized conjugate (100X concentration) 
5) Wash buffer (20X concentration) 
6) Enzyme substrate and enzyme stopping solution. 
 
4.11.3. Materials required but not provided 
       1) 37
0
C incubator, calibrated pipettes 
       2) Microplate shaker, washer and reader 
 
4.11.4. Procedure 
4.11.4.1. Sample Collection and Handling  
1)  1 ml of blood was collected in each of the three tubes provided with the kit. The tubes 
supplied were: 
a) The nil control tube with no antigens added, serving as a negative control 
b) The mitogen tube - which served as a positive control and as an inbuilt control for the 
correct handling of the blood samples and incubation. It also provided information 
about the individual’s immune status. 
c) The TB antigen tube - coated with ESAT-6, CFP-10 and TB 7.7 antigen.  
2) The tubes were mixed by shaking vigorously up and down 10 times to ensure that the entire 
inner surface of the tube had been coated with the blood. 
3) The tubes were then transported to the lab and handed over to the lab personnel. 
4) The tubes were shaken vigorously again and incubated at 37
0
C for 16-24 hours. 
5) After incubation the tubes were centrifuged at 2000 rcf for 15 minutes. 
6) The plasma (supernatant) was then transferred to appropriately labeled vials and stored at  
 25  
-20
0
C. They were later shipped from the field laboratory to the laboratory in St. John’s 
Research Institute, Bangalore in cryoshippers where the QFT-GIT assay was performed.  
 
4.11.4.2. Assay protocol  
1) The supernatants (plasma) from the QFT-GIT tubes and the reagents, except the conjugate 
were brought to room temperature (22
0
C ± 5
0
C) prior to testing. 
2) 28 samples were processed in a batch. The batch number and date of assay was noted down. 
3) A sample template was prepared before performing the assay to note and add the samples in 
the respective wells.  
4) The freeze dried kit standards were reconstituted with distilled water as mentioned on the 
vials.  
Reconstitution of the standard to the stated volume produced a solution with a concentration of  
8.0 IU/mL 
5) Preparation of standards:  
          a) Four tubes were taken and labeled as S1, S2, S3 and S4. 
          b) 150µl of the green diluent was added to S1 and 210 µl to S2, S3 and S4 respectively. 
          c) 150 µl of the kit standard was added to S1 and mixed thoroughly. 
          d) 70 µl was transferred from S1 to S2 and mixed thoroughly. 
          e) 70 µl was then transferred from S2 to S3 and mixed thoroughly 
          f) The green diluent alone in S4 served as the zero standard. 
g) Thus S1 contained 4IU/mL, S2 1 IU/mL, S3 0.25 IU/mL and S4 contained 0 IU/mL   
respectively. The standards were assayed in triplicates.  
6) The freeze-dried Conjugate 100X concentrate was reconstituted with distilled water as 
mentioned on the vial. 
7) Working strength conjugate was prepared by diluting the required amount of reconstituted 
conjugate 100X concentrate in green diluent to obtain a final concentration of 1X and was 
prepared according to the number of strips used. 
8) Prior to the assay, plasma was mixed to ensure the even distribution of IFN-γ. 
9) 50 µl of the freshly prepared working strength conjugate was added to the required ELISA 
wells using a multichannel pipette. 
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10) 50 µl of the test plasma was added to the appropriate wells using a multichannel pipette 
according to the template prepared. Finally 50 µl of the standards 1 to 4 were added in 
triplicates. 
11) The conjugate and plasma samples/standards were mixed thoroughly for 1 minute using a 
microplate shaker.   
12) The plates were covered with a lid and incubated at room temperature (22
0
C ± 5
0
C) for 120 
minutes ± 5 minutes. 
13) During the incubation period wash buffer, 20X concentrate was diluted to prepare a 
working solution of final concentration of 1X. At the end of the incubation period the wells 
were washed with 400 µl each of the wash buffer for 6 cycles with a 5 second soak time. 
14) Then 100 µl of the enzyme substrate solution was added to each well and mixed thoroughly 
using a microplate shaker. 
15) The plate was covered with a lid and incubated at room temperature (22
0
C ± 5
0
C) for 30 
minutes in the dark. 
16) Following the 30 minute incubation, 50µl of the enzyme stopping solution was added to 
each well and mixed thoroughly using the microplate shaker. 
17) The Optical Density (OD) of each well was measured within 5 minutes of stopping the 
reaction using the microplate reader fitted with a 450nm filter and a 620nm-650nm reference 
filter. OD values were used to calculate the results. 
 
4.11.5. Interpretation of results 
 The results were interpreted using the following criteria provided by the manufacturer 
as shown in Table b and Figure c below. 
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Table b. Interpretation of results when nil, TB antigen and mitogen tubes are used 
Nil 
(IU/mL) 
TB antigen 
minus Nil 
(IU/mL) 
Mitogen 
minus Nil 
(IU/mL) 
Quantiferon-TB 
(IU/mL) 
Report/ Interpretation 
         <0.35 ≥ 0.5 
≥ 0.35 and <25% 
of nil value 
≥ 0.5 
 
Negative 
 
M. tuberculosis infection 
NOT likely 
≥ 0.35 and ≥25% 
of nil value 
Any Positive M. tuberculosis infection 
likely 
 
        < 0.35 
< 0.5 
 
 
 
 
 
≤ 8.0 
≥ 0.35 and <25% 
of nil value 
< 0.5 
 
>8.0 
 
         Any 
 
Any 
 
 
 
Indeterminate 
 
 
Results are indeterminate 
for TB antigen response 
Adapted from QFT-GIT kit insert (31) 
 
Figure c. Interpretation flow diagram when nil, TB antigen and mitogen tubes were used 
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 As mentioned by the manufacturer, diagnosing or excluding TB disease and assessing 
probability of latent TB infection (LTBI), requires a combination of epidemiological, 
historical, medical and diagnostic findings that should be taken into account when interpreting 
the results. The standard curve was plotted using the TB QuantiFERON Software provided by 
Cellestis. 
 
4.12. Data management and analysis 
4.12.1. Data entry and documentation  
 The clinical research forms (CRF’s) were used to capture the data generated in the 
diagnostic process and the laboratory investigations. The medical staff maintained a source 
document into which all the data pertaining to the study were included which comprised of 
both the medical report and the laboratory report. A requisition form was maintained by the 
medical officer and a laboratory data collection form was maintained by the laboratory staff. 
Good clinical practice (GCP) guidelines were followed for entry of the data into the 
documents/forms and for rectifying the entered data. The data were simultaneously entered into 
a database and the hard copies were archived. 
 
4.12.2. Data analysis 
 Patient information was entered in the EpiInfo software and the data was analyzed 
using PASW program version 18.0. Binary logistic regression was used for the analysis. The 
indeterminate QFT results were considered as negative in the statistical analysis. All the binary 
categorical variables were coded as 0 and 1. The string variables were converted to numerical 
variables for statistical analysis. Univariate analysis was performed to identify individual 
factors which were significantly associated with TST and QFT-GIT positivity during the first 
diagnostic visit and was restricted to those who had both TST and QFT results. In a 
multivariate model, age, gender, education of the father (surrogate of the socio-economic 
status), cough>2 weeks (surrogate of symptoms), contact (surrogate of exposure to TB), FTT 
(surrogate of nutritional status) and isolation of NTM in any gastric and/or induced sputum 
sample were included. A p-value of <0.05 was considered significant. Kappa value (κ) was 
used to express the concordance between the QFT-GIT and TST. 
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4.12.3. Anthropometric data analysis 
 Taking age and gender into consideration, the differences in measurements were 
expressed as standard deviation or Z score units. The international nutrition community 
commonly uses the Z-score since “using Z-scores allows us to identify a fixed point in the 
distributions of different indices and across different ages and useful summary statistics can be 
calculated from them” (80). 
 Z-score is defined as the difference between the value for an individual and the median 
value of the reference population for the same age or height, divided by the standard deviation 
of the reference population (80)   
 
This can be written in equation form as: 
 
Z-score (or SD-score) = (Observed value) – (Median reference value) 
       Standard deviation of reference population 
 
 The cut-off used for Z score was -2 standard deviation. Thus a child with a Z-score <-2 
for weight-for-age was considered underweight; a child with a Z-score of <-2 for weight-for-
height was considered as wasting and a child with a Z-score of <-2 for height-for-age was 
considered stunted.   
 
4.13. Confounders 
  The number of repeated visits to the CVW for the same child could influence the TST 
outcome. Hence the data was segregated according to the number of visits and analyzed. 
 Since TST was performed on all the participants at the end of two year follow up period 
as part of the study design and since all with a TST ≥10mm were referred to the CVW, there 
were a higher percentage of children of the higher age group with a TST positive result 
referred to the CVW. Thus, while it is plausible that TST positive results are more common in 
older children, because of greater exposure to TB, in this study it was also related to the study 
design.  
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4.14. Ethical Considerations 
The study was conducted according to the Declaration of Helsinki, Protection of human 
subjects (21 CFR 50), Institutional Review boards (21 CFR 56) and Obligations of Clinical 
Investigations (21 CFR 312) as well as the Indian Council of Medical Research Guidelines, 
2006. The protocol and informed consent form, and all protocol amendments were reviewed 
and approved by the Institutional Review Board (IRB) and Independent Ethics Committee 
(IEC) of the AERAS global TB vaccine foundation and St. John’s Medical College prior to any 
procedures being conducted. The study was also approved by the Ministry of Health Screening 
Committee of the Government of India. Written informed consent was obtained from each 
subject’s legally authorized representative prior to any procedures being conducted. 
Confidentiality was maintained by using coded numbers and initials to identify the 
laboratory specimens, source documents, study reports etc. All records were maintained in a 
secure archive with access available only to designated study personnel. 
 
5.0. RESULTS 
 There were 4,382 children enrolled in this study. Of these, 2,215 were included in the 
active surveillance and 2,167 were included in the passive surveillance group. Seven hundred 
and forty six participants were referred to the TB CVW as described below: 638 (85.5%) were 
from the active surveillance group and 108 (14.5%) from the passive surveillance group. Out 
of the 746, 53 came for a second visit (45-active surveillance, 8– passive surveillance), three 
(two-active surveillance, one- passive surveillance) for a third visit and one (active 
surveillance) for a fourth visit.  
 
5.1. Referral to the Case Verification Ward (CVW) 
5.1.1. First visit      
 The children were referred to the CVW based on either symptoms suggestive of TB, 
failure to thrive (FTT) and/or a recent contact with an index case with TB disease. In our study 
there were 62.6% (467/746) admitted to the CVW based on FTT alone, 11.9% (89/746) based 
on symptoms alone and 5.6% (42/746) based on contact alone. 19.3% (144/746) were admitted 
based on either two of the above-mentioned criteria and 0.6% (4/746) based on all three i.e. 
FTT, symptoms and contact.  
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5.1.2. Second visit 
 During the second visit, 54.7% (29/53) were admitted based on FTT alone, 1.9% (1/53) 
based on symptoms alone and 5.7% (3/53) based on contact alone. 35.8% (19/53) were 
admitted based on either two of the above-mentioned criteria and 1.9% (1/53) based on all 
three.  
 
5.1.3. Third visit 
 During the third visit, one child was admitted based on FTT, one based on symptoms 
and one based on FTT and symptoms. 
 
5.1.4. Fourth visit 
 During the fourth visit, there was only one child referred to the CVW and that was 
based on both symptoms and contact. 
 
5.2. Characteristics of the participants referred to the CVW 
 Out of the 746 children referred to the CVW (first visit only), both TST and QFT-GIT 
was performed on 709 children. The baseline characteristics of these 709 children are given in 
Table 1. Approximately two thirds (66.3%) of the children were ≥12 months of age. The 
proportion of parents (mothers; 70.7%, fathers; 81.6%) that were literate (with an education of 
primary school or greater) was higher as compared to those that were illiterate (mothers; 
29.3%, fathers; 18.4%). Nearly half (49.9%) of the children were under weight (WAZ), 43.2% 
wasting (WHZ) and 26.6% stunted. Data were missing for two children for WHZ and one child 
for HAZ as anthropometry was not done. Approximately two thirds (76.6%) of the children 
had FTT. Chest X-ray was negative in 97.7% of the children; 1.7% had abnormal X-rays 
suggestive of TB and 0.6% had other radiological abnormalities. 
 
5.3. Characteristics of the definite and probable cases of TB 
 There were totally four definite cases of TB and nine cases of probable TB. Out of 
these 13 cases, three of those with definite TB were both TST and QFT-GIT positive. In these 
3 children, the IFN-γ response to the mitogen was high (> 10 IU/mL) as also to the TB antigen 
(>8.5 IU/mL). The fourth participant diagnosed as a definite case of TB had a TST of 9mm and 
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was negative for QFT-GIT with an IFN-γ response to the TB antigen of only 0.26 IU/mL. In 
addition, 13 participants who were smear negative but culture positive had invalid results with 
the HAIN-MTBC kit such that the universal control and genus control bands were negative. 
These samples are being reassessed and may have implications for the identification of other 
genotypically confirmed TB cases. There was one participant of the 9 diagnosed as ‘probable 
TB’ (PID-012-0009) with a TST of 16mm who was negative for QFT-GIT. None of the 
‘probable TB’ cases had IFN-γ responses to the TB antigens that were any where near as high 
as the three who had ‘definite TB’ and were QFT-GIT positive (Table 2). 
 
5.4. TST and QFT-GIT results for the definite, probable, unlikely and not TB 
 Seven hundred and twenty nine participants were classified as ‘definite TB’, ‘probable 
TB’, ‘unlikely TB’ and ‘not TB’. The diagnosis was unavailable for the remaining participants 
because of incomplete data.  
a. Definite TB: There were two cases of definite TB diagnosed during the first visit and two 
during the second visit. Three of these were negative for smear but showed growth on culture 
(LJ) and was confirmed by speciation using the HAIN kit. These three were also positive for 
both TST and QFT-GIT. One case was positive on smear microscopy and was confirmed by 
speciation using the Roche real time kit. This case was negative for TST and QFT-GIT    
(Table 3).  
b. Probable TB: There were eight cases of probable TB diagnosed during the first visit and one 
during the second visit. Of these one was positive for TST but negative for QFT-GIT while the 
rest were negative for both (Table 3). 
c. Unlikely TB: There were 126 diagnosed as “unlikely TB” during the first visit and eight 
during the second visit. Out of the 126, 11 were positive and 85 were negative for both TST 
and QFT-GIT. 30 were positive for either TST or QFT-GIT. Out of the 8, 2 were positive and 6 
were negative for both TST and QFT-GIT. (Table 3) 
d. Not TB: 552 were classified as “not TB” during the first visit and 30 during the second visit. 
Out of the 552, 5 were positive and 509 were negative for both TST and QFT-GIT. Thirty eight 
were positive for either of the two tests. Out of the 30, 2 were positive and 25 were negative for 
both TST and QFT-GIT. Three were positive for TST but negative for QFT-GIT (Table 3)  
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5.5. TST and QFT-GIT positive 
  In our study 10.2% (n=72/709) were TST positive and 5.8% (n=41/709) were QFT 
positive.   
  
5.6. Association of the clinical, demographic, nutritional and 
mycobacteriological (excluding M.tuberculosis) factors with TST and QFT-
GIT 
5.6.1. TB exposure 
5.6.1.1. Association with TST 
 Children with a recent history of contact with TB (taken as a pre-requisite for TB 
infection) had significantly increased odds of being TST positive (OR 2.11 [95% CI 1.07; 
4.17], p=0.03) in a univariate analysis (Table 4). In a multivariate analysis the association was 
statistically not significant (OR 1.58 [95% CI 0.69; 3.63], p=0.27) (Table 5). 
 
5.6.1.2. Association with QFT 
 In a univariate analysis, the odds of children with a recent history of contact with TB 
being positive for QFT-GIT were increased (OR 3.46 [95% CI 1.50; 7.81], p=<0.01) (Table 4) 
and remained so in a multivariate analysis (OR 4.36 [95% CI 1.79; 10.54], p=0.01) (Table 5). 
 
 The odds of children with recent history of contact with TB being positive for 
combined TST and QFT-GIT was increased (OR 7.08 [95% CI 2.51; 19.65], p=<0.01) (Figure 
1) 
 
5.6.2. Demographic and Nutritional factors 
5.6.2.1. Association with TST 
 In a univariate analysis children with wasting based on the weight for height Z score 
(OR 0.31 [95% CI 0.17; 0.56], p= <0.01) and whose fathers were illiterate (OR 0.37 [95% CI 
0.15; 0.88], p=0.03) had reduced odds of being TST positive (Table 4) The odds of being TST 
positive were also reduced for children who had FTT (OR 0.19 [95% CI 0.12; 0.33], p= <0.01] 
(Table 4).  
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 In a multivariate analysis, the odds of children with FTT (OR 0.14 [95% CI 0.07; 0.26], 
p= <0.01) being TST positive was reduced (Table 5). 
 
5.6.2.2. Association with QFT-GIT 
 The FTT (OR1.09 [95% CI 0.49; 2.52], p=0.82) was not significantly associated with QFT-
GIT positivity in a univariate (Table 4) or multivariate analysis FTT (OR 1.58 [95% CI 0.64; 3.87], 
p=0.33) (Table 5). None of the demographic factors were associated with QFT-GIT positivity in a 
univariate (Table 4) or in a multivariate (Table 5) analysis. 
 
5.6.3. NTM 
5.6.3.1. Association with TST 
 The odds of children with atleast one NTM isolated from culture (OR 0.47 [95% CI 0.24; 
0.92], p=0.03) being TST positive was reduced (Table 4). This association continued to be 
significant in a multivariate analysis (OR 0.44 [95% CI 0.21; 0.93], p=0.03) (Table 5).  
 
5.6.3.2. Association with QFT-GIT 
 The odds of children with atleast one NTM isolated from culture (OR 1.20 [95% CI 0.56; 
2.54], p=0.61) being QFT-GIT positive was not significant (Table 4). This association was also not 
significant in a multivariate analysis (OR 1.21 [95% CI 0.58; 2.52], p=0.62) (Table 5).  
 
5.7. Agreement between QFT-GIT and TST 
 The agreement between TST (cut off ≥10mm) and QFT-GIT was fair [κ 0.31(95% CI 
0.19; 0.40), p= <0.01] when all participants were included in the analysis. At a cut off of ≥ 
5mm for TST poor agreement was seen [κ 0.09(95% CI 0.04; 0.11), p=<0.01]. When the 
analysis was restricted to those with a history of contact with TB, the agreement between TST 
(cut off ≥10mm) and QFT-GIT was good [κ 0.68(95% CI 0.39; 0.82), p= <0.01] and at a cut 
off of ≥ 5mm for TST was fair [κ 0.23 (95% CI 0.08; 0.22), p=0.01] (Table 6) 
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5.8. Characteristics of children with Indeterminate QFT-GIT results 
 There were 26 participants with an indeterminate QFT-GIT result accounting for 3.6% 
(26/718) of the total QFT-GITs performed. When these were compared with children who had 
either a positive or negative QFT-GIT, the group with indeterminate test results had a higher 
percentage of children who were <1 year of age (84.6% Vs. 30.7%; p<0.001) and had cough 
>2 weeks (42.3% Vs 15.4%; p=<0.01). The reason for an indeterminate test result was due to 
low IFN-γ produced in response to mitogen in 24/26 (92.3%) or a high value of IFN- γ 
produced in the nil tube in 2/26 (7.7%). 
 
 5.9. Association of age with IFN-γ produced in response to mitogen 
  The IFN-γ produced in response to mitogen (phytohemagluttinin) at a cut off of  
≥5 IU/ml were significantly related to age; increasing age was associated with higher values 
(Figure 2).  
 
6.0 DISCUSSION 
6.1. Discussion based on results 
 Without an accurate diagnostic test it is very difficult to measure the precise burden of 
childhood TB. As mentioned earlier, unlike the case of adolescents, where culture serves as a 
gold standard for the diagnosis of TB, it may not be the same scenario in children < 5 years of 
age (6). Treatment is often initiated on the suspicion of TB. Thus in the absence of a gold 
standard, TST serves as the only test widely used as an aid in the diagnosis or rather screening 
of childhood tuberculosis. However this test has its own limitations (3).  
 In our study we compared the TST with the QFT-GIT in young children. TST and 
QFT-GIT were positive for 75% (3/4) of the definite cases of TB. These three cases had a high 
IFN-γ produced in response to mitogen and TB antigen. Two probable cases of TB had 
indeterminate QFT results due to low IFN-γ produced in response to mitogen and TB antigen. 
However, in the rest of the participants even though the IFN-γ produced in response to mitogen 
was high, the IFN-γ produced in response to TB antigen was low. One of the issues in 
childhood TB is determining the clinical relevance of ‘probable’ TB cases. While the algorithm 
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that we used was decided a priori, at the start of the study, there have been several 
publications, some fairly recently, that have indicated that there is poor agreement between 
clinical scoring methods (12, 81).  Further analyses are possible with other clinical scores, but 
the overriding issue is still the absence of a gold standard for smear and culture negative TB 
(81). Although our data on the IFN-γ responses to the TB antigen in bacteriologically 
confirmed TB is on a small sample, the particularly high IFN-γ responses to the TB antigen in 
3 of 4 definite TB cases, suggests that further studies may be able to define a cutoff for TB 
disease which can supplement the current clinical scores in the diagnosis of bacteriologically 
negative TB.   
 Exposure to M. tuberculosis represented by a recent history of contact with TB (a pre-
requisite for TB infection) showed an association with TST (OR 2.11 [95% CI 1.07; 4.17], 
p=0.03) in a univariate analysis. This association was higher for QFT-GIT (OR 3.46 [95% CI 
1.50; 7.81], p=<0.01). This is similar to the results found by Arend et al (27) where QFT-GIT 
was more strongly associated with recent exposure to M. tuberculosis than TST. Thus children 
who were exposed to an infectious source were more likely to be QFT-GIT positive than TST 
positive. In a multivariate analysis the association between history of TB contact and TST (OR 
1.58 [95% CI 0.69; 3.63], p=0.27) was lost, however the association with QFT-GIT (OR 4.36 
[95% CI 1.79; 10.54], p=0.01) continued to be strong. This suggests that the association 
between TST and exposure to M. tuberculosis i.e recent history of contact with an infectious 
source may be affected by other factors like nutritional status. The association with a recent 
history of contact with TB was stronger for children who were positive for combined TST and 
QFT-GIT. This shows that a recent history of contact with TB is strongly associated with TST 
and QFT and even more strongly with positivity to combined TST and QFT-GIT (Figure 1). 
The stronger association between exposure to M.tuberculosis and combined TST and QFT-GIT 
positivity also suggests that a two step approach i.e. QFT-GIT test on those who have a TST 
positive may have some utility. When we compare the association of history of contact with 
TB with TST, QFT-GIT and combined TST and QFT-GIT (Figure 1), we see that the 
confidence intervals overlap. Thus, even though there is an increased odds in children with a 
history of contact with TB being positive for combined TST and QFT-GIT, the overlap in the 
CI may suggest that the number of positives for TST, QFT-GIT and combined TST and QFT-
GIT with a recent history of contact with TB may be small. Thus, future prospective studies 
evaluating the two tests with more number of children with history of contact with TB may be 
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able to bring out the association between history of contact with TB and TST, QFT-GIT and 
combined TST and QFT-GIT.  
 Malnourished, under-weight and immuno-compromised children may give false 
negative TST results (23). In our study children who had FTT had reduced odds of being TST 
positive in a univariate (OR 0.19 [95% CI 0.12; 0.33], p= <0.01) and multivariate (OR 0.14 
[95% CI 0.07; 0.26], p=<0.01) analysis. 68.5% (13/19) of the children who had a history of 
contact and FTT were negative for TST. This may be due to the fact that children with an FTT 
may have suppressed immune responsiveness. Even if they do have an TB infection, they may 
not be able to produce enough chemokines to cause a hypersensitivity reaction in the skin and 
hence may not produce any induration in the TST. Thus, it may be that as in the case of HIV 
(82), QFT-GIT which is unaffected by nutritional status, may have a specific role in 
populations with a high burden of under nutrition. 
 At a TST cut off of ≥10mm there was fair agreement (κ= 0.31) with QFT-GIT which 
was better than at a TST cut off of ≥ 5mm (κ=0.09) where the agreement was poor. When we 
considered children with a history of contact, the agreement between the two tests at a TST cut 
off of ≥10mm was good (κ=0.68), suggesting that both the tests perform well in children with a 
history of exposure to TB. In another study by Dogra et al,(56) based on hospitalized children 
in rural India good agreement (κ=0.73) was found between the TST (cut off ≥ 10 mm) and  
QFT-GIT. Although these two studies were conducted in India and on a pediatric population, 
they cannot be directly compared as the one by Dogra et al is a hospital-based study with a 
sample size of 105. Nonetheless, it is encouraging that the results are somewhat comparable.   
 Age is known to be related to response in the TST (3). However, in our study we could 
not relate the TST to age since the protocol required all infants with a TST ≥ 10mm to be 
referred into the case verification ward leading to a bias in the presentation of TST results and 
this was done only at study close out (i.e. 2 years) which might be expected to lead to a greater 
number of people being TST positive at 2 years than at earlier ages compared to those who 
received a TST only after referral into the CVW. Thus, while it is plausible that increasing age 
is associated with a positive TST, our study design does not allow us to specifically test this 
association.    
 In our study, children with NTM were less likely to be TST positive suggesting that 
NTM may not have had an effect on the TST. This observation, is similar to that seen in 
another study in Gambia which showed that during early life, TST is not affected by NTM 
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(83). Atleast one NTM isolated on culture did not have association with QFT-GIT positive. 
The antigens used in QFT-GIT i.e ESAT-6, CFP-10 and TB 7.7, are present in three NTM, 
namely M. kansasii, M. szulgai and M. marinum. In our study, we isolated M. kansasii from 
three children all of whom had a negative QFT. The significance of QFT positivity and NTM 
isolation in clinical samples needs to be further explored in children. While diagnostic criteria 
for NTM disease in children are not clearly defined, available criteria (84) suggest that the 
children in this study who had NTM’s isolated were unlikely to fulfill criteria for NTM disease 
and that these were likely, commensals.  
 Children are thought to have a weak immune system at birth and as they grow, the 
immune system develops (85). This is in agreement with the IFN-γ produced in response to 
mitogen recorded in the QFT-GIT assay, where with increasing age the IFN- γ produced in 
response to mitogen also increased (0-5 months [69.2%], 6-11 months [72.4%], 12-17 months 
[86.1%] and ≥18 months [96.4%]). The numbers of children with indeterminate results were low 
(3.6%). When compared to the children with either QFT-GIT positive or negative, the 
indeterminate group had a higher percentage of children (84.6% Vs. 30.7%; p<0.01) from the 
younger age group (<1 year) suggesting that since the younger children are thought to have a 
weaker immune system which leads to a lower IFN-γ produced in response to mitogen, they 
will tend to have more indeterminate results rather than a positive or negative QFT-GIT result. 
However more number of studies evaluating the QFT-GIT test in children <1 year of age are 
required to enumerate this. 
 
6.2 Methodological issues 
6.2.1. Validity 
Internal validity: “Internal validity is the degree to which the results of a study are correct for 
the sample of patients being studied” (80). 
External validity: “External validity is the degree to which the results of an observation hold 
true in other settings” (80). 
 
6.2.1.1. Internal Validity 
 A number of factors could have affected the internal validity of this study. Different 
staff personnel administered the tuberculin to the children and measured the TST reading. 
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There could have been variation in the injection of the tuberculin and could lead to a reader 
bias which could affect the TST reading. The height and weight measurements were also 
measured by different staff personnel. Similar to the tuberculin administration, different staff 
personnel collected the gastric aspirate and induced sputum. This could lead to variations in the 
amount and quality of gastric aspirate collected. However, standard operating procedures 
(SOPs) were used for all field, clinical and laboratory procedures. Equipment was calibrated 
regularly and the training of staff was extensive and well documented. Missing data were 
minimal.  
 The contamination of the LJ (11.9%) and MGIT (1
st
 inoculation- 26.5%,  
reinoculation I-12.3% and reinoculation II 2-7.4%) used for the growth of the M. tuberculosis 
could theoretically have led to a reduced number of isolates of M. tuberculosis/NTM. 
However, a high percentage of NTMs were isolated (approximately in 26% of participants) and 
since NTMs are fragile organisms it would suggest that the probability of not detecting MTB 
was minimal. 
  
6.2.1.2. External validity 
 This study has a high external validity for rural populations in India with similar 
background TB rates; the enrollment and follow up of eligible births were high, loss to follow 
up during the two year period was minimal (98/4382).  
 
7.0. CONCLUSION  
 TST positivity was higher than QFT-GIT positivity. Positive TST and QFT-GIT was 
significantly associated with a recent history of TB contact; this association was stronger when 
both TST and QFT-GIT were used in unison. However the association between TB exposure 
and TST was significantly affected by under nutrition. The concordance between the TST and 
QFT-GIT in BCG vaccinated children was fair. The number of indeterminate QFT results was 
low (3.6%). Thus QFT-GIT could be compared with the TST for diagnosis of TB infection in 
young children. Due to a lack of gold standard to compare the two tests with and the low 
number of culture confirmed cases we could not calculate the sensitivity or specificity of the 
tests in relation to TB disease. More number of studies on children with larger number of 
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culture confirmed cases need to be carried out to evaluate both the tests in relation to TB 
disease in children.     
 
8.0 LIMITATIONS 
 The numbers of bacteriologically confirmed cases of TB were low in this population 
and thus we were unable to determine the sensitivity or specificity of the tests in relation to TB 
disease. While recent exposure to M. tuberculosis was captured, the gradient of exposure was 
not; this would have been useful to assess in relation to TST and QFT-GIT. The diagnosis of 
‘probable TB’ was done using a single algorithm – this could be extended using other clinical 
scores that utilize the parameters that were captured for this study – however, the absence of a 
gold standard would continue to be a concern in the interpretation of ‘probable TB’. 
 
9.0 FURTHER RESEARCH 
 Lessons from this study suggest that the following areas may be important to pursue: 
1. The evaluation of combined TST /QFT-GIT in the evaluation of progression of 
infection to disease. 
2. The evaluation of combined TST / QFT-GIT in high risk populations (e.g. contacts of 
bacteriologically confirmed TB) would allow for the greater likelihood of identifying 
larger numbers of bacteriologically confirmed TB in children (a limitation of this 
study). 
3. The determination of an IFN-γ response to TB antigen cutoff in the QFT-GIT to 
supplement the existing scores for the diagnosis of ‘probable TB’.  
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11.0 TABLES 
Table 1. Baseline characteristics of the participants referred to the CVW the first time and on 
whom both TST and QFT were performed. (n=709)   
  
  
n (%) 
 
 
Age (n=709) 
0-5 months 
6-11 months 
12-17 months 
≥ 18 months 
 
Gender (n=709) 
Male  
Female 
 
Mother education (n=709) 
Illiterate 
Others 
 
Father education (n=707)* 
Illiterate 
Others 
 
Wall (n=709) 
Bricks 
Others 
 
Cooking fuel (n=709) 
Wood  
Others 
 
Cough ≥2 weeks (n=709) 
Yes 
No 
 
Contact (n=709) 
Yes 
No 
 
X-ray (n=709) 
Abnormal-TB 
Abnormal-Not TB 
Negative 
 
 
 
 
65 (9.2%) 
174 (24.5%) 
245 (34.6%) 
225 (31.7%) 
 
 
372 (52.5%) 
337 (47.5%) 
 
 
208 (29.3%) 
501 (70.7%) 
 
 
130 (18.4%) 
577 (81.6%) 
 
 
540 (76.2%) 
169 (23.8%) 
 
 
638 (90.0%) 
71 (10.0%) 
 
 
129 (18.2%) 
580 (81.8%) 
 
 
67 (9.4%) 
642 (90.6%) 
 
 
12 (1.7%) 
  4 (0.6%) 
693 (97.7%) 
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Table 1 (Continued). Baseline characteristics of the participants referred to the CVW the first 
time and on whom both TST and QFT were performed. (n=709)   
 
  
       n (%) 
 
 
FTT (n=709) 
Yes 
No 
 
WHZ (n=707)* 
<-2(wasting) 
≥ 2 (normal) 
 
HAZ (n=708)* 
<-2(stunted) 
≥ 2 (normal) 
 
WAZ (n=709) 
<-2(under weight) 
≥ 2 (normal) 
 
 
 
 
 
 
543 (76.6%) 
166 (23.4%) 
 
 
305 (43.2%) 
402 (56.8%) 
 
 
188 (26.6%) 
520 (73.4%) 
 
 
354 (49.9%) 
355 (50.1%) 
*- data missing for the remaining 
WAZ – Weight for age z score 
WHZ – Weight for height z score 
HAZ- Height for age z score 
 (cut-off used for Z score is -2 standard deviation) 
 FTT – Failure to thrive based on any of the following criteria after evaluation of the weight for age growth chart: 
1). Loss of weight or no gain in weight over two consecutive visits  
2). Crossing of two centile lines, downwards on growth chart 
3). Weight consistently remaining below the third percentile line 
X-ray- At least 2 out of 3 radiologists reported chest x-rays considered for “Abnormal- suggestive of TB” and 
“Abnormal-Not TB”. 
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Table 2. Characteristics of the definite and probable cases of TB 
 
 
   PID – Participant Identification 
   CVW – Case verification ward 
   TB – Tuberculosis 
   TST – Tuberculin skin test 
   QFT-GIT - QuantiFERON Gold In-tube assay  
   Nil - without antigens added, serving as a negative control for QFT-GIT 
   Mitogen - serving as a positive control for QFT-GIT. It also provided information about the         
    individual’s immune status 
   TB antigen – mixture of ESAT-6, CFP-10 and TB 7.7 antigen  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PID 
 
Visit 
to the 
CVW 
 
Age 
(months) 
 
Gender 
 
DefiniteTB/ 
Probable TB 
 
TST 
(mm) 
 
QFT-GIT 
 
Mitogen 
values 
 
TB 
antigen 
values 
 
Nil 
values 
 
 
039-0009 
144-0006 
307-0008 
315-0016 
006-0004 
012-0009 
107-0001 
148-0005 
157-0004 
207-0002 
279-0009 
376-0005 
407-0005 
 
 
1st 
2nd 
2nd 
1st 
1st 
1st 
1st 
1st 
1st 
2nd 
1st 
1st 
1st 
 
 
18 
26 
 9 
28 
10 
24 
18 
15 
 8 
14 
10 
16 
13 
 
M 
M 
M 
M 
F 
F 
F 
M 
M 
M 
F 
F 
F 
 
Definite 
Definite 
Definite 
Definite 
Probable 
Probable 
Probable 
Probable 
Probable 
Probable 
Probable 
Probable 
Probable 
 
 9 
20 
10 
13 
6 
16 
0 
4 
5 
4 
2 
4 
5 
 
Negative 
Positive 
Positive 
Positive 
Indeterminate 
Negative 
Negative 
Negative 
Indeterminate 
Negative 
Negative 
Negative 
Negative 
 
 
>10 
>10 
>10 
>10 
0.59 
>10 
>10 
>10 
0.31 
>10 
1.31 
3.98 
>10 
 
 
0.26 
>10 
8.73 
>10 
0.09 
0.38 
0.07 
0.27 
0.17 
0.36 
0.15 
0.04 
0.09 
 
0.15 
0.4 
0.32 
0.25 
0.1 
0.15 
0.08 
0.18 
0.29 
0.96 
0.13 
0.06 
0.08 
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Table 3.  Tuberculin skin test and QuantiFERON TB Gold In-tube assay results for the definite, 
probable, unlikely and Not TB (first and second visit) 
 
        
       TST – Tuberculin skin test 
        QFT-GIT - QuantiFERON Gold In-tube assay  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            1st visit                2nd visit   
 
n 
             TST 
≥10mm      <10mm 
 
 
n 
               TST 
≥10mm         <10mm 
 
Definite TB        
             QFT-GIT   Positive 
                                Negative 
 
Probable TB       
             QFT-GIT   Positive 
                                Negative 
 
Unlikely  TB      
             QFT-GIT   Positive 
                                Negative 
 
Not TB         
             QFT-GIT   Positive 
                                Negative 
 
 
2 
 
 
 
8 
 
 
 
126 
 
 
 
552 
 
      
      
     2             0 
     0             0 
 
      
     0             0       
     1             7 
 
 
11             3 
27           85 
 
 
5             18 
20          509 
 
2 
 
 
 
1 
 
 
 
8 
 
 
 
30 
    
      
     1                 0 
     0                 1 
 
 
 0                  0 
 0                  1 
 
 
  2                 0 
  0                 6 
 
 
  2                  0 
  3                  25 
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Table 4. Univariate associations of demographic, clinical, nutritional and mycobacteriological 
factors (excluding M. tuberculosis) with the tuberculin skin test and QuantiFERON TB Gold 
In-tube assay (first visit).  
 
           TST            QFT-GIT   
   n ≥10mm      <10mm 
  n (%)          n (%) 
 
Unadjusted OR 
95% CI 
 
Positive  Negative 
  n (%)       n (%) 
 
Unadjusted OR 
95% CI 
 
 
Age 
0-5 months 
 
6-11 months 
 
12-17 months 
 
≥18 months
1 
 
 
Gender 
Male  
 
Female
1 
 
 
Mother education 
Illiterate 
 
Others
1 
 
 
Father education 
Illiterate 
 
Others
1 
 
 
Wall 
Bricks 
 
Others
1 
 
 
Cooking fuel 
Wood  
 
Others
1 
 
 
Cough ≥2 weeks 
Yes 
 
No
1 
 
 
709 
 
 
 
 
 
 
 
 
 
709 
 
 
 
 
 
709 
 
 
 
 
 
707* 
 
 
 
 
 
709 
 
 
 
 
 
709 
 
 
 
 
 
709 
 
 
 
 
 
 
 
4 (5.6)           61(9.6) 
 
6 (8.3)        168(26.4) 
 
12(16.7)     233(36.6) 
 
50(69.4)     175(27.4) 
 
 
 
42(58.3)     330(51.8) 
 
30(41.7)     307(48.2)   
      
 
 
19(26.4)     189(29.7) 
 
53(73.6)     448(70.3)    
 
 
 
6 (8.3)        124(19.5) 
 
66(91.7)     511(80.5) 
 
 
 
53(73.6)     487(76.5) 
 
19(26.4)     150(23.5) 
 
     
 
63(87.5)     575(90.3) 
 
9 (12.5)        62(9.7) 
    
 
  
 8(11.1)     121(19.0) 
 
64(88.9)     516(81.0) 
 
     
 
 
      0.23 
(0.08;0.66)** 
      0.13  
(0.05; 0.29)** 
      0.18  
(0.09; 0.34)** 
        1.0 
 
 
      
      1.30  
(0.79; 2.13) 
        1.0 
 
 
      
       0.85  
(0.49; 1.47) 
       1.0   
 
 
       
       0.37  
(0.15; 0.88)** 
       1.0 
 
 
       
       0.85  
(0.49; 1.49) 
       1.0 
 
 
       
      0.75  
(0.35; 1.59) 
       1.0 
 
 
       
      0.53 
 (0.24; 1.14) 
       1.0 
 
 
 
 
6(14.6)         59(8.8) 
 
6(14.6)       168(25.2) 
 
8(19.6)       237(35.5) 
 
21(51.2)     204(30.5) 
 
 
 
24(58.5)     348(52.1) 
 
17(41.5)     320(47.9) 
 
 
 
14(34.1)     194(29.0) 
 
27(65.9)     474(71.0) 
 
 
 
9(22.0)      121(18.2) 
 
32(78.0)    545(81.8) 
 
 
 
32(78.0)    508(76.1) 
  
 9(22.0)    160(23.9) 
 
 
 
36(87.8)    602(90.1) 
  
 5(12.2)      66(9.9) 
 
 
 
4(9.8)        125(18.7) 
 
37(90.2)    543(81.3) 
 
 
 
       0.99 
 (0.34; 2.74) 
       0.35 
 (0.12; 0.93)** 
       0.33 
 (0.13; 0.80)** 
        1.0 
 
 
        
       1.30  
(0.66; 2.58) 
         1.0 
 
 
        
       1.27  
(0.62; 2.58) 
          1.0 
 
 
        
       1.27 
 (0.55; 2.86) 
          1.0 
 
 
        
       1.12 
 (0.50; 2.58) 
         1.0 
 
 
        
       0.79  
(0.28; 2.37) 
          1.0 
 
 
        
       0.47  
(0.14; 1.41) 
           1.0    
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Table 4 (Continued). Univariate associations of demographic, clinical, nutritional and 
mycobacteriological factors (excluding M. tuberculosis) with the tuberculin skin test and 
QuantiFERON TB Gold In-tube assay (first visit) 
 
           TST QFT-GIT   
n 
≥10mm     <10mm 
   n (%)       n (%) 
 
Unadjusted OR 
95% CI 
 
Positive  Negative 
  n (%)       n (%) 
 
Unadjusted OR 
95% CI 
 
 
Contact 
Yes 
 
No
1
 
 
 
FTT 
Yes 
 
No
1 
 
 
WHZ 
<-2(wasting) 
 
≥ 2 (normal)
1 
 
 
HAZ 
<-2(stunted) 
 
≥ 2 (normal)
1 
 
 
WAZ 
<-2(under weight) 
 
≥ 2 (normal)
1 
 
 
NTM 
Atleast 1 positive 
 
Negative
1 
 
 
709 
 
 
 
 
 
709 
 
 
 
 
 
707* 
 
 
 
 
 
708* 
 
 
 
 
 
709 
 
 
 
 
 
707
a
 
 
 
 
 
 
 
12(16.7)        55(8.6) 
 
60(83.3)     582(91.4) 
 
 
 
32(44.4)     511(80.2) 
 
40(55.6)     126(19.8) 
 
 
   
15(20.8)     290(45.7) 
 
57(79.2)     345(54.3) 
 
 
 
22(30.6)     166(26.1) 
 
50(69.4)     470(73.9) 
 
 
 
30(41.7)     324(50.9) 
 
42(58.3)     313(49.1) 
 
 
 
11(15.7)     181(28.4) 
 
59 (84.3)    456(71.6) 
 
 
 
      2.11 
(1.07; 4.17)** 
      1.0 
 
       
        
       0.19  
(0.12; 0.33)** 
      1.0 
 
 
 
        0.31 
(0.17;0.56)** 
       1.0 
 
 
      
       1.24  
(0.73; 2.12) 
       1.0 
 
 
      
       0.69  
(0.42; 1.13) 
       1.0 
 
 
 
       0.47  
(0.24; 0.92)** 
           1.0 
 
 
10(24.4)       57(8.5) 
 
31(75.6)     611(91.5) 
 
 
 
32(78.0)     511(76.5) 
  
9(22.0)      157(23.5) 
 
 
 
18(43.9)     287(43.1) 
 
23(56.1)     379(56.9) 
 
 
 
14(34.1)     174(26.1) 
 
27(65.9)     493(73.9) 
 
 
 
24(58.5)     330(49.4) 
 
17(41.5)     338(50.6) 
 
 
 
12(30.8)     180(26.9) 
 
27(69.2)     488(73.1 
 
 
 
       3.46 
(1.50; 7.81)** 
        1.0      
 
        
        
       1.09  
(0.49; 2.52) 
        1.0 
 
 
 
       1.03  
(0.52; 2.04) 
         1.0 
 
 
        
       1.47  
(0.71; 2.99) 
          1.0 
 
 
       
        1.45 
 (0.73; 2.87) 
        1.0 
 
 
 
       1.20 
 (0.56; 2.54) 
       1.0 
 
* - data missing for the remaining 
a 
– culture confirmed MTB cases excluded 
**-p values <0.05 
1
-reference group 
WAZ – Weight for age Z score , WHZ – Weight for height Z score. HAZ- Height for age Z score 
(cut-off used for Z scores is -2 standard deviation) 
TST- Tuberculin skin test, QFT-GIT-QuantiFERON Gold In-tube assay, OR-Odds ratio, CI- Confidence 
interval 
FTT – Failure to thrive  
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Table 5. Multivariate associations of demographic, clinical, nutritional and 
mycobacteriological factors (excluding M. tuberculosis) with the tuberculin skin test and 
QuantiFERON TB Gold In-tube assay (first visit) 
 
             TST              QFT-GIT   
 
  n 
≥10mm      <10mm 
  n (%)          n (%) 
Adjusted OR 
95% CI 
 
Positive  Negative 
  n (%)       n (%) 
Adjusted OR 
95% CI 
 
 
 
 
Age 
0-5 months 
 
6-11 months 
 
12-17 months 
 
>= 18 months
1 
 
 
Gender 
Male  
 
Female
1 
 
 
 
Father education 
Illiterate 
 
Others
1 
 
 
Cough ≥2 weeks 
Yes 
 
No
1 
 
 
 
 
 
 
709 
 
 
 
 
 
 
 
 
 
709 
 
 
 
 
 
 
 
707* 
 
 
 
 
709 
 
 
 
 
 
 
 
 
4 (5.6)           61(9.6) 
 
6 (8.3)        168(26.4) 
 
12(16.7)     233(36.6) 
 
50(69.4)     175(27.4) 
 
 
 
42(58.3)     330(51.8) 
 
30(41.7)     307(48.2)   
      
 
 
 
6 (8.3)        124(19.5) 
 
66(91.7)     511(80.5) 
 
 
 
 8(11.1)     121(19.0) 
 
64(88.9)     516(81.0) 
 
     
 
   
  
 
 
       0.23 
(0.11; 0.46)** 
       0.09 
(0.04; 0.26)** 
       0.11 
(0.04; 0.37)** 
       1.0 
 
 
 
       1.38 
(0.78; 2.44) 
       1.0 
 
 
 
 
       0.41 
(0.16; 1.05) 
        1.0 
 
 
 
       0.47 
(0.19; 1.19) 
       1.0 
 
 
 
 
 
 
 
6(14.6)         59(8.8) 
 
6(14.6)       168(25.2) 
 
8(19.6)       237(35.5) 
 
21(51.2)     204(30.5) 
 
 
 
24(58.5)     348(52.1) 
 
17(41.5)     320(47.9) 
 
 
 
 
9(22.0)      121(18.2) 
 
32(78.0)    545(81.8) 
 
 
 
4(9.8)        125(18.7) 
 
37(90.2)    543(81.3) 
 
 
 
 
 
 
 
       0.96 
(0.34; 2.77) 
       0.31 
(0.11;0.86) 
       0.34 
(0.15; 0.81) 
       1.0 
 
 
 
       1.31 
(0.66; 2.55) 
       1.0 
 
 
 
 
       1.26 
(0.56; 2.82) 
       1.0 
 
 
 
       0.68 
(0.22; 2.14) 
       1.0 
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Table 5 (Continued).  Multivariate associations of demographic, clinical, nutritional and 
mycobacteriological factors (excluding M. tuberculosis) with the tuberculin skin test and 
QuantiFERON TB Gold In-tube assay (first visit) 
 
            TST               QFT-GIT   
n 
≥10mm      <10mm 
  n (%)          n (%) 
Adjusted OR 
95% CI 
 Positive  Negative 
  n (%)       n (%) 
Adjusted OR 
95% CI 
 
 
Contact 
Yes 
 
No
1 
 
 
FTT 
Yes 
 
No
1
 
 
 
NTM 
Atleast 1 positive 
 
Negative1 
 
 
709 
 
 
 
 
 
709 
 
 
 
 
 
707
a 
 
 
 
 
 
 
12(16.7)        55(8.6) 
 
60(83.3)     582(91.4) 
 
 
 
32(44.4)     511(80.2) 
 
40(55.6)     126(19.8) 
 
 
 
11(15.7)     181(28.4) 
 
59 (84.3)    456(71.6) 
 
 
       1.58 
(0.69; 3.63) 
       1.0 
 
 
 
       0.14 
(0.07; 0.26)** 
       1.0 
 
 
 
       0.44 
(0.21; 0.91)** 
       1.0 
     
 
 
10(24.4)       57(8.5) 
 
31(75.6)     611(91.5) 
 
 
 
32(78.0)     511(76.5) 
 
 9(22.0)      157(23.5) 
 
 
 
12(30.8)     180(26.9) 
 
27(69.2)     488(73.1 
 
 
       4.36 
(1.79; 10.54)** 
       1.0 
 
 
 
       1.58 
(0.64; 3.87) 
       1.0 
 
 
 
       1.21 
(0.58; 2.52) 
       1.0 
 
* - data missing for the remaining 
**-p values <0.05 
1
-reference group 
a 
- culture confirmed MTB excluded 
WAZ – Weight for age Z score  
WHZ – Weight for height Z score  
HAZ- Height for age Z score 
(cut-off used for Z scores is -2 standard deviation) 
FTT – Failure to thrive 
TST- Tuberculin skin test 
 QFT-GIT-QuantiFERON Gold In-tube assay 
 OR-Odds ratio 
 CI- Confidence interval 
 Multivariate analysis: adjusted for age, gender, education of the father (surrogate of the socio-economic status), 
cough>2 weeks (surrogate of symptoms), contact (surrogate of exposure to TB), FTT (surrogate of nutritional 
status) and NTM. 
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 Table 6. Overall agreement between Tuberculin skin test and QuantiFERON TB Gold In-tube 
assay (First visit) 
 
                QFT-GIT 
   Positive             Negative   
      n (%)                n (%) 
 
Kappa (95% CI) 
 
p value 
TST 
 n=709                 
              ≥10mm 
             < 10mm 
 
       
      
   20(48.8)             52(7.8) 
   21(51.2)           616(92.2) 
 
 
 
0.31 (0.19; 0.40) 
Fair 
 
 
 
<0.01  
With history of 
contact 
TST n=67                 
              ≥10mm 
             < 10mm 
                   
 
 
      8(80.0)             4(7.0) 
      2(20.0)            53(93.0) 
 
 
 
0.68 (0.39; 0.82) 
Good 
 
 
 
 
<0.01 
                    QFT-GIT 
   Positive          Negative   
      n (%)                n (%) 
   
 
 
 
TST  
n=709             
              ≥5mm 
             < 5mm 
 
 
     
    32(78.8)        285(42.7)                                                            
      9(22.0)         383(57.3) 
 
 
 
0.09 (0.04; 0.11) 
Poor 
 
 
 
 
<0.01
With history of 
contact 
TST n=67                 
              ≥5mm 
             < 5mm 
 
 
 
 
    10(100.0)          29(50.9) 
  0(0.0)           28(49.1) 
 
 
 
0.23(0.08; 0.22) 
Fair 
 
 
 
0.01 
    
    TST – Tuberculin skin test 
     QFT-GIT - QuantiFERON Gold In-tube assay  
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Figure 1. Comparison of the association between TST, QFT-GIT and combined TST and 
QFT-GIT with recent history of contact with TB 
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OR – Odds ratio 
CI  - Confidence interval 
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    QFT-GIT - QuantiFERON Gold In-tube assay  
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Figure 2. Association of age with IFN-γ produced in response to mitogen. 
 
69.2
72.4
86.1
96.4
0
20
40
60
80
100
120
0--5 6--11 12--17 >=18
Age (months)
P
e
rc
e
n
ta
g
e
≥5
 
 
*y – axis: Percentage of children with ≥5 IU/mL of IFN- γ in response to mitogen 
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12.0 APPENDICES 
12.1. CASE VERIFICATION WARD VISIT SOURCE DOCUMENT 
 
CASE VERIFICATION WARD DIAGNOSTIC VISIT 
(Unscheduled) 
 
Date Case Verification Ward Admission Informed Consent signed :  __ __ / __ __ / __ __ __ __ 
               d d        m m              y y y y 
Date of admission to Case Verification Ward:    __ __ / __ __ / __ __ __ __ 
                        d d        m m              y y y y 
Referral from (check one):  Self-referral         
    Active follow-up visit         
    Passive surveillance (check one):   
         Hospital/primary health centre/private practitioner     
          Microscopy centre;    Emmaus Swiss Hospital  
            Other 
                                                          Field study team (between scheduled visits for Active group, or 
passive surveillance for Passive group)  
 
Was the child diagnosed with TB prior to this admission to the Case Verification Ward?    Yes     
No 
    
If child has history of symptoms and/or TB + contact and/or physician  
diagnosed/suspects TB, child is eligible for admission to CVW.  If child is on and  
Adherent to TB medication for more than 8 weeks,the child is not eligible to be  
admitted to the CVW.  
 
Does the child meet admission criteria?        Yes         No 
 
Physical assessment   Date of assessment     __ __ / __ __ / __ __ __ __   
(Place leading zero if necessary.)     d d           m m              y y y y                      
          
   Weight ___ ___ . ___  kg 
 
   Height ___ ___ . ___ cm   
 
   Temperature  ___ ___ °C 
 
   Respiratory rate ___ ___ ___ per min   
   
   SaO2   ___ ___ ___ %     
 
   Heart rate ___ ___ ___ bpm    
 
   Head circumference     ___ ___ .  ____cm 
 
   Mid-arm circumference  ___ ___ . ___ cm 
 
 
 
 
 
Study Team Member Code 
 
   
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CASE VERIFICATION WARD DIAGNOSTIC VISIT (continued) 
(Unscheduled) 
 
Parent interview Date of interview     __ __ / __ __ / __ __ __ __  
               d d           m m              y y y y     
Is child experiencing (per parental report):   
 
Recent illness               Yes; specify________________________________ How many days ______       
        Treated:    Yes; specify treatment ________________________________ 
                                          No  
             No    
 
Recent loss of weight          Yes     
                                No 
 
Loss of appetite             Yes; how many days ______   
                          No 
 
Cough                          Yes; how many days ______       
         Treated:    Yes; specify treatment ________________________________ 
                                           No  
             No     
 
Fever                            Yes; how many days ______       
          Treated:    Yes; specify treatment 
________________________________ 
                                           No  
             No    
 
Has child had a significant exposure (e.g. approximately 8 hours) to an individual on TB treatment?   
            Yes     
            No 
 
Was child started on TB therapy prior to admission to Case Verification Ward?    
                                    Yes; number of days already on treatment:  ______ days     
                                        (Record on TB Treatment Record case report form.)     
            No 
             
Respondent/source of information (check all that apply):   
     
           Mother    
             Father     
             Guardian    
             Other; specify: ___________________________________________________ 
 
 
Study Team Member Code 
 
   
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CASE VERIFICATION WARD DIAGNOSTIC VISIT (continued) 
(Unscheduled) 
 
Brief review of systems: physical exam 
 
HEENT        Normal        Abnormal;  
____________________________________________ 
 
Dermatologic        Normal        Abnormal;  
____________________________________________ 
 
Neurologic        Normal        Abnormal;  
____________________________________________ 
 
Respiratory        Normal        Abnormal;  
____________________________________________ 
 
Cardiovascular        Normal        Abnormal;  
____________________________________________ 
 
Gastrointestinal        Normal        Abnormal;  
____________________________________________ 
 
Urogenital        Normal        Abnormal;  
____________________________________________ 
 
Musculoskeletal       Normal        Abnormal;  
____________________________________________ 
 
 
Failure to thrive (FTT)?         Yes        No 
 
 
 
 
 
 
__________________________________________________________________________________________________________________ 
Name     Signature 
 
Tuberculin skin test  (Test will be read within 2 – 4 days after application.  Test should be applied day of admission.) 
 
    
Date applied:   __ __ / __ __ / __ __ __ __                     
                                     d d            m m             y y y y 
 
 
 
Date read:       __ __ / __ __ / __ __ __ __ 
                 d d           m m             y y y y                                
 
Result (Record widest transverse measurement in whole number):  _____  mm       
 
 
 
 
__________________________________________________________________________________________________________________ 
Name     Signature      
Study Team Member Code 
 
   
Study Team Member Code 
 
   
Study Team Member Code 
 
   
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CASE VERIFICATION WARD DIAGNOSTIC VISIT (continued) 
(Unscheduled) 
 
Chest radiograph (A-P)      Date:   __ __ / __ __ / __ __ __ __                                           
                  d d          m m             y y y y 
 
  Normal       
  Abnormal, TB      
  Abnormal, not TB     
Impression 
 
Apex:  
 
 
 
 
 
Hilar: 
 
 
 
 
 
Mid-zone: 
 
 
        Right                  Left 
 
 
Lower zone: 
 
 
 
 
 
NOTES: 
____________________________________________________________________________ 
___________________________________________________________________________________
_ 
___________________________________________________________________________________
_ 
 
__________________________________________________________________________________
_ 
Name     Signature     Date 
 
 
 
 
 
 
Study Team Member Code 
 
   
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CASE VERIFICATION WARD DIAGNOSTIC VISIT (continued) 
(Unscheduled) 
 
SMEAR   
 
1 of 2:  Induced sputum    Date obtained:   __ __ / __ __ / __ __ __ __        
                                   d d        m m             y y y y 
     
Consistency:   Salivary  Result:    Positive; specify if       Scanty 
    Mucoid            1+      
      Muco purulent         2+   
         
     Blood stained         3+     
           Negative  
  
1 of 2:  Gastric wash    Date obtained:   __ __ / __ __ / __ __ __ __        
                                    d d        m m             y y y y 
 
    Result:    Positive; specify if       Scanty 
           1+      
           2+            
          3+     
      Negative  
 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
- -   
 2 of 2:  Induced sputum    Date obtained:   __ __ / __ __ / __ __ __ __        
                                    d d        m m             y y y y 
 
Consistency:   Salivary  Result:    Positive; specify if       Scanty 
    Mucoid            1+      
      Muco purulent         2+   
         
     Blood stained         3+     
            Negative   
    
 
2 of 2:  Gastric wash    Date obtained:   __ __ / __ __ / __ __ __ __        
                                    d d        m m             y y y y 
 
    Result:    Positive; specify if       Scanty 
          1+      
           2+            
          3+     
      Negative  
 
 
NOTES:   
___________________________________________________________________________ 
___________________________________________________________________________________ 
___________________________________________________________________________________________
__________________________________________________________________________________ 
 
___________________________________________________________________________________ 
Name                              Signature     Date   
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CASE VERIFICATION WARD DIAGNOSTIC VISIT (continued) 
(Unscheduled) 
 
CULTURE     
      
1 of 2:  Induced Sputum    Date obtained:   __ __ / __ __ / __ __ __ __        
                      d d         m m             y y y y 
 
      Positive 
     Negative           
     Contaminated 
 
If culture result is positive, record PCR speciation.  Otherwise, check Not applicable.       
 
    Not applicable  (Check if culture was negative; Do not complete below.)   
   
    PCR:    
   
     MTB     Positive          Negative        
    MOTT       Positive          Negative           
  
     BCG disease     Positive          Negative          
   
    
  
If culture result is positive, record drug sensitivities.  Otherwise, check not applicable.      
 
    Not applicable (Check if culture was negative or contaminated; Do not complete below.)   
 
Drug sensitivities: 
 
  Streptomycin    Sensitive         Resistant       
   Isoniazide    Sensitive         Resistant       
   Rifampicin    Sensitive         Resistant       
  Ethambutol    Sensitive         Resistant       
 
 
 
NOTES:   
___________________________________________________________________________ 
___________________________________________________________________________________
_ 
___________________________________________________________________________________________
_ 
___________________________________________________________________________________
_ 
___________________________________________________________________________________
_ 
 
___________________________________________________________________________________
_   
Name                              Signature     Date   
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CASE VERIFICATION WARD DIAGNOSTIC VISIT (continued) 
(Unscheduled) 
 
CULTURE     
      
1 of 2:  Gastric Wash     Date obtained:   __ __ / __ __ / __ __ __ __        
                      d d         m m             y y y y 
 
      Positive 
     Negative           
     Contaminated 
 
If culture result is positive, record PCR speciation.  Otherwise, check not applicable.       
 
    Not applicable (Check if culture was negative; Do not complete below.)   
   
    PCR:    
   
     MTB     Positive          Negative        
    MOTT       Positive          Negative           
  
     BCG disease     Positive          Negative          
   
    
  
If culture result is positive, record drug sensitivities.  Otherwise, check not applicable.      
 
    Not applicable (Check if culture was negative or contaminated; Do not complete below.)   
 
Drug sensitivities: 
 
  Streptomycin    Sensitive         Resistant       
   Isoniazide    Sensitive         Resistant       
   Rifampicin    Sensitive         Resistant       
  Ethambutol    Sensitive         Resistant       
 
 
 
NOTES:   
___________________________________________________________________________ 
___________________________________________________________________________________
_ 
___________________________________________________________________________________________
_ 
___________________________________________________________________________________
_ 
___________________________________________________________________________________
_ 
 
___________________________________________________________________________________
_   
Name                              Signature     Date   
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12.2. SUBJECT INFORMATION AND CONSENT FORM  
 
SUBJECT INFORMATION AND CONSENT FORM 
 
ADMISSION TO TB CASE VERIFICATION WARD AND DIAGNOSTIC WORK-UP  
 
EMMAUS SWISS LEPROSY PROJECT / ST. JOHN’S INSTITUTE OF POPULATION 
HEALTH AND CLINICAL RESEARCH  
 
Study Number:  EPI-003-IN 
 
Study Title:       
A Prospective Epidemiological Study of TB Disease in Neonates in Palamaner Taluk, South India 
to Determine the Incidence of Pulmonary Tuberculosis and the Impact of Surveillance 
Methodology on the Measurement  
 
Introduction 
• We want you to know that your child’s participation in this study is optional. 
• You may choose not to have your child take part in this study. 
• You can decide later to take your child out of the study. 
• You will lose no benefits if your child does not take part in the study. 
 
Before you decide whether or not to allow your child to participate in the study please take as much 
time as you need to ask any questions and to discuss the study with members of the study team, family 
members, friends or others.  
 
Who is the sponsor of the study? 
Aeras Global TB Vaccine Foundation, USA, is the sponsor of the study.  This is a research study being 
done by the Emmaus Swiss Leprosy Project, Palamaner and the St. John’s Institute of Population 
Health and Clinical Research, Bangalore, in partnership with the Aeras Global TB Vaccine Foundation, 
USA. The person in charge of the study is Professor Mario Vaz, Head of Population Health, St. John’s 
Institute of Population Health and Clinical Research, Bangalore.  There are no costs to you for any of 
the processes outlined below if you decide to allow your child to participate.  
 
Why are you asking my child to take part in this study? 
Your child is already enrolled in the research study of TB disease in this community, and the study 
doctors want to find out if your child has TB. 
   
As part of this research study, if your child has symptoms of TB or has been exposed to someone who 
has TB, the study doctors will examine your child and perform tests to see if your child has TB.  You 
are being asked to give your permission to have your child admitted to the special TB diagnostic ward 
that has been set up for this study in the Emmaus Swiss Hospital in order for these tests to be done.   
 
What is the purpose of this research study? 
The primary purpose of this study is to find out how many infants and children get TB disease during 
the first two years of life in this community. The diagnosis of TB in infants and children is very 
difficult.  Your child can have TB but have no symptoms.  However, the symptoms of TB are very 
much like other diseases.  The best way to diagnose TB is to grow the germ that causes TB.  The 
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doctors doing this study have built a special ward at Emmaus Swiss Hospital to diagnose TB in infants 
and children.  
 
 
The decision to enroll your child in the study is voluntary, and you can decide to stop your child’s 
participation (in other words, withdraw your child) at any time.  If you decide you want to withdraw 
your child from the study, you should inform a study team member in order for them to have accurate 
records about the research.   
 
If you decide not to enroll your child in the study you should know that standard tests and health care 
are available through the government health services and private practitioners.   
 
What does my child have to do in this study? 
You may either bring your child to the TB diagnostic ward because you think your child has symptoms 
of TB, or another doctor may refer your child to the study doctor for follow-up at the diagnostic ward.   
When you arrive, the study doctor will ask you some questions about your child’s health and any 
symptoms of TB they have, and whether or not your child has been exposed to someone who has TB.  
The study doctor will then decide if your child needs to be admitted for further testing.     
 
If your child is admitted to the TB diagnostic ward, you will be able to stay in the ward overnight 
with your child.  Your child will need to be admitted for about 2 nights.  Your child will be examined 
and a chest radiograph (chest X-ray) will be taken.   Your child will also be given a TB skin test.  The 
TB skin test is called a Mantoux and is done by injecting a very small amount of substance under the 
skin with a needle on the forearm.  It will form a small bump right after the injection that will last for 
about 10 minutes.  About a day or two later, it may form a pimple that looks like a mosquito bite if your 
child has a positive reaction to the test (meaning, your child may have been exposed to TB.)  A study 
team member will “read” the test by looking at your child’s arm where the injection was made about 
two to three days after the test was done.      
 
The study doctor and nurse will need to get a sputum sample from your child in order to test it 
for the TB germ.  Sputum is the mucus matter that is coughed up from your child’s lower airways.  In 
order to help your child cough up the sputum, a light mist or vaporized spray of liquid material will be 
given to your child to breathe in.  This is called a nebulizer.  The nebulizer will help your child cough 
up sputum.  It may be necessary to pat your child on the back to help with coughing.  This procedure is 
called sputum induction.  The sputum induction procedure will be done again the next day in order for 
the doctors to have two samples of sputum.   
 
The study doctor and nurse will also need to get a sample of your child’s gastric fluid (liquid) in 
order to test it for the TB germ.  Gastric fluid is the liquid that is found in your child’s stomach.  In 
order to remove some of the fluid from your baby’s stomach, a thin soft flexible tube will be placed in 
your child’s mouth and then passed further into the stomach.  Some of the gastric fluid will then be 
gently sucked out.  This procedure is called gastric aspirate.  The gastric aspirate procedure will be done 
again the next day in order for the doctors to have two samples of gastric fluid.   
 
The study doctor and nurse will also need to get a blood sample from your child. This sample will 
be taken from the forearm of your child and the total volume that is taken is 6 ml (a little more than 1 
teaspoon full). Before taking the blood, the doctor / nurse will prick the heel with a needle to get a 
couple of drops of blood to test for haemoglobin. This test will tell the doctor whether your child is 
producing blood well. If the value in this test is low, the doctor may decide to reduce the blood sample 
or not to take the blood sample at all. 
 
What happens after the testing is done in the TB diagnostic ward? 
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After your child has had the second sputum induction and the second gastric aspirate, and after the TB 
skin test has been read, your child will be discharged from the ward.  Transportation home will be 
provided.  All of the results of the tests performed may not be available before your child is discharged 
from the TB diagnostic ward.  Some of the results may not be known for up to 8 week.  However, the 
study doctor will provide you with a letter to explain the results of the tests that are known at the time 
and will follow up with another letter later if your child has TB.  Your child’s doctor, if you have 
specified one, will also receive a copy of all of the results that are sent to you.   
 
What happens if my child has TB? 
If your child is diagnosed with TB before being discharged from the diagnostic ward, the study doctors 
will either start your child on anti-TB medication or will give you a one-week supply of anti-TB 
medication.  You should start your child on the medication immediately after leaving the diagnostic 
ward.  The medication provided will follow treatment guidelines of the tuberculosis control program of 
the Indian government health services.   
 
If at any time your child is diagnosed with TB, your child’s doctor and the District TB Officer will be 
notified to ensure that your child receives the necessary follow-up care and medication.  Treatment for 
TB disease takes at least six months.   
 
Why would my child not get these tests? 
If your child has a history of wheezing, the sputum induction will not be done. There may be other 
reasons this test or other tests might not be done.  The doctor will discuss these reasons with you. 
 
Can my child get hurt by being in the study? 
Your child may experience a brief burning sensation immediately after injection of the TB skin test.  A 
blister, ulceration (break in the skin), fever, or lymph node swelling may occur if the child is sensitive 
to the substance, but this is very rare.   
 
Your child may also experience a brief burning sensation when the prick on the heel is done and the 
blood sample from the forearm is collected. Sometimes there may be a bruise where the blood has been 
collected. The skin may appear darker and this usually disappears after a few days.  
 
The chest X-ray is the most common radiologic procedure. The chest X-ray will expose your child very 
briefly (often less than one-half second) to a very small amount of radiation.   Young children are more 
sensitive to the risks of radiation, but experts consider the benefits of the chest X-ray to be much greater 
than any potential risks from the brief, small radiation exposure your child will undergo.   
 
Sputum induction is not a routine procedure.  However, this procedure has been used in a similar TB 
diagnostic ward in South Africa for more than three years with over 1,600 children.  None of them had 
a severe reaction.  A doctor from this study visited the ward in South Africa and learned the procedure 
and has since done these tests on other infants, here in Palamaner.  Since this is not a routine procedure 
your child will be closely monitored for adverse reactions such as spasms that narrow the child’s 
airways similar to asthma.  Sputum induction may cause your child some minor brief discomfort.  Your 
child may also experience shortness of breath, a feeling of tightness in the chest, coughing, gasping or 
wheezing.  If this happens, your child will be treated with drugs to stop the spasms and open the 
airways.  To prevent this from happening, the doctors may exclude your child from sputum induction if 
your child has a history of asthma or symptoms similar to asthma. 
 
The gastric aspirate procedure is routinely performed in hospitals.  There is a small chance that the tube 
will enter the airway instead of the stomach. There is also a small chance that some of the stomach 
fluids may enter your child’s lung which could later lead to pneumonia.  If either of these happen, your 
child may cough, gasp, and have trouble breathing. This is reversed by taking the tube out.   
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Are there any benefits to being in the study? 
The special TB diagnostic ward set up for this research study uses tests that are not available in the 
public health clinics in India.    The major benefit to your child is that there will be a very complete 
diagnosis done for TB.   
 
Mothers’ and infants will receive all meals while in the TB diagnostic ward at Emmaus Swill Hospital.  
Transportation will be provided to and from Emauss Hospital for the TB diagnosis.  No other form of 
payment is available. 
 
What if my child gets hurt while in the study? 
If your child gets hurt as a direct result of being in the study the doctors and nurses working on the 
study will ensure your child gets treatment for any pain or injuries that result from taking part in the 
study.  The researchers will not pay money to you if your child gets hurt in the study 
 
How will my child’s information be kept private? 
Except for the consent form, your child will be identified by a study code on all study records, and not 
by name.  You will receive a copy of this consent form.  Every effort will be made to keep your child’s 
study records strictly confidential.  The researchers will be allowed to see your child’s records.  Your 
child’s records must also be made available for review upon request by regulatory agencies that oversee 
this research. 
 
Who can I contact if I have questions? 
The Institute Ethics Review Board of St. John’s Medical College, Bangalore, and the Research in 
Human Subjects/Institutional Review Board of the Aeras Foundation, which reviews the ethics of all 
studies with human subjects, have approved this study.  
 
If you ever have questions or concerns about this study, your rights, or if you are injured as a result of 
being in this study you should contact: 
 
St. John’s Medical College, Research Ethics Committee 
Name: Professor Karuna R Kumar (Convener) 
Address: St. John’s Medical College, Bangalore 560034 
Phone: 080-22065057 
 
Principal Investigator: 
Professor Mario Vaz, Population Health Group, St. John’s Institute of Population Health and Clinical 
Research, St. John’s National Academy of Health Sciences, Bangalore 560034, India. Telephone 080-
22065059, Fax 080-25532037 email: mariovaz@iphcr.res.in   
 
Operational Manager: 
Dr. AJW Jacob, Director, Emmaus Swiss Leprosy Project, LS Farm, PO Palamaner 517408, Chittoor 
Dt. A.P. Telephone 08579-252255 
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INFORMED CONSENT: Admission to Case Verification Ward and Diagnostic Work-up 
 
Study Number:  EPI-003-IN 
Study Title: 
A Prospective Epidemiological Study of TB Disease in Neonates in Palamaner Taluk, 
South India to Determine the Incidence of Pulmonary Tuberculosis and the Impact of 
Surveillance Methodology on the Measurement  
I have read and discussed this consent form.  My questions have been answered. I freely agree for 
my child participate and be examined for tuberculosis. 
  
 
Child’s Name ________________________________________________________ 
 
 
___________________________________________________________________ 
Parent/Guardian’s Name                   Parent/Guardian’s Signature or                 Date 
(please print)                                      Thumb Print 
 
 
___________________________________________________________________                          
Name of study personnel taking consent          Signature                                  Date 
(please print) 
  
 
Interpreter: 
     
 Interpreter used   OR       Interpreter not used     
 
 
Witness: 
 
   Witness used   OR       Witness not used  
 
    
__________________________________________________________________               
Name (please print)                                               Signature                              Date 
 
 
Please indicate whether witness is: 
                   
 Study personnel  OR    Independent / Impartial person 
 
 
 
Note: The subject must be given a copy of this consent form.  A signed copy must be filed in 
the subject's medical record at the Study Offices. 
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